
















The Dissertation Committee for Christopher Ryan Young Certifies that this 
is the approved version of the following dissertation: 
 
 
PROPERTIES OF SPHERICAL PELLETS 









James W. McGinity, Supervisor 
Alan B. Combs 
Isaac C. Sanchez 
Christian P. Whitman 
Robert O. Williams, III 
PROPERTIES OF SPHERICAL PELLETS  










Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
Doctor of Philosophy 
 
 


















I wish to thank my family for making this endeavor possible. Mom and 
Dad, you shaped me into the person I am today. Although you joked with me 
about being a perpetual student, your love, support and encouragement were 
unwavering. I also appreciate the support of my brother and grandparents. 
I would like to thank my supervisor, Dr. James W. McGinity, for his 
generous support, encouragement and guidance during my undergraduate and 
graduate studies at The University of Texas at Austin. I am sincerely grateful for 
his advice that was not limited to my academic and professional careers. I truly 
believe that his influence has made me a better person.   
I am grateful to Dr. Robert O. Williams, III for his advice, expertise and 
encouragement. I would also like to thank the other members of my dissertation 
committee, Dr. Alan B. Combs, Dr. Isaac C. Sanchez and Dr. Christian P. 
Whitman, for their time and advice. 
I would like to thank Dr. John J. Koleng for his guidance during my 
undergraduate and graduate studies. His enthusiasm and love of pharmaceutics 
set an example for me, and he was very influential in my decision to embark on 
this academic endeavor.  
 vi
I am very grateful to Weijia Zheng for her advice and encouragement, 
both academically and personally. She has always supported me, even when 
times were rough. I feel extremely fortunate to have had her as a lab mate and 
friend during these 5 years. 
I am grateful to my friends for their assistance and cooperation during my 
studies. Shirley, I appreciate you giving me a place to stay when I was homeless. 
I would also like to thank Matteo and Sara for their tremendous generosity, and 
Hector for his friendship. 
Lastly, I would like to extend my appreciation to my recently graduated 
colleagues and friends: Dr. Feng Zhang, Dr. Chuanbin Wu, Dr. Michael Repka, 
Dr. Yucun Zhu and Dr. Diane Bruce. Furthermore, I would like to thank fellow 
graduate students for their support: Shellie Callahan, Caroline Dietzsch, Shawn 
Kucera, Dave Miller and Dorothea Sauer. 
 
 vii
PROPERTIES OF SPHERICAL PELLETS  






Christopher Ryan Young, Ph.D. 
The University of Texas at Austin, 2004 
 
Supervisor:  James W. McGinity 
 
Melt-extrusion is an efficient, continuous and solvent-free process that 
has been studied to prepare granules, sustained-release tablets and transdermal 
drug delivery systems. The research in this dissertation investigated the 
physicochemical properties of spherical pellets produced by a novel melt-
extrusion process. 
Pellets are widely employed in controlled-release systems. Wet-mass 
extrusion and spheronization is the more established method of producing 
spherical pellets, but this technique utilizes water and requires additional 
processing steps to produce controlled-release beads. Thus, a novel melt-
extrusion technique was characterized to manufacture spherical pellets, and the 
controlled drug release properties of the resulting beads were examined. 
Furthermore, the physical properties of matrix pellets produced by either wet-
 viii
mass or melt-extrusion were investigated, including morphology, porosity and 
particle size distribution. 
Although marketed controlled-release dosage forms exhibit significant 
differences in the design and composition, these preparations can be broadly 
categorized as single or multiple unit systems. Multiple unit dosage forms offer 
several advantages, such as improved bioavailability and reduced risks of dose 
dumping, local irritation and tampering. The physical and drug release properties 
of tablets compressed from melt-extruded pellets were investigated. Furthermore, 
the influences of compression force, filler excipient and pellet to excipient ratio 
on the properties of pellet containing compacts was investigated using drug 
release, hardness, friability and disintegration time determinations. 
The physicochemical properties of a melt-extruded system containing 
poly(ethylene oxide) and guaifenesin were studied. The calculated Hansen 
solubility parameters and thermal properties of materials were used to determine 
suitability of systems for thermal-processing. Following extrusion, the influence 
of accelerated storage conditions on the drug release and physical properties of 
pellets was studied. Furthermore, film-coating of melt-extruded beads with 
Eudragit® L 30 D-55 was studied to design a melt-extruded pellet system with 
pH-dependent drug release properties. 
Melt-extrusion processes were studied to manufacture controlled release 
matrix systems based on Acryl-EZE®, which is a pre-mixed excipient blend 
based on a methacrylic acid copolymer. The physical and chemical stability of 
materials during thermal processing was studied using thermal gravimetric 
analysis and HPLC. Modeling of drug release and swelling/erosion studies were 
 ix
employed to determine the influence of swelling agents on the mechanism and 
kinetics of drug release from thermally processed dosage forms.  
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Chapter 1: Introduction 
 
1.1 CONTROLLED-RELEASE DRUG DELIVERY SYSTEMS 
1.1.1 Controlled-release drug therapy 
Conventional drug therapy involves the periodic dosing of a therapeutic 
agent that has been formulated to ensure stability, activity and bioavailability of 
the active pharmaceutical ingredient (API). Nevertheless, many drugs present 
difficulties when administered by conventional methods due to toxicity and low 
therapeutic index problems. Controlled-release systems have been designed to 
maintain plasma drug levels in the therapeutic range and thus minimize the 
effects of such problems (Gandhi 1999, Sood 2003). 
1.1.2 Design of controlled-release systems 
The rate of drug input into the body or dosing rate is determined by the 
rate of drug release from the delivery device. Multiple kinetic models and 
equations can be used to describe the drug release kinetics from controlled-
release systems, but formulations that give zero-order drug release in vivo are 
widely accepted as ideal form many drug therapies (Guinchedi 1989). However, 
controlled-release products have been studied to produce many different release 
profiles. Systems exhibiting first-order drug release kinetics are also frequently 
employed to achieve the goals of controlled drug release therapies.  
Thus, a zero- or first-order release model is often considered when 
calculating the desired drug release kinetics (Ritschel 1988). The controlled drug 
release system is then formulated and developed to achieve the desired drug 
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release profile (Ritschel 1989). Although there are significant differences in the 
design and composition of marketed controlled-release dosage forms, these 
preparations can be broadly categorized as either single or multiple unit dosage 
forms. 
1.1.3 Single unit dosage forms 
Single unit dosage forms are defined as oral delivery systems that consist 
of one unit that contains a single dose of the drug and is intended to be 
administered singularly (Gandhi 1999). Many single unit dosage forms have been 
developed for the controlled-release of bioactive materials. The most widely 
investigated example is the monolithic matrix-based tablet (Katznendler 1997, 
Nellore 1998, Pickler 1998). The advantages of this dosage form include high 
drug loading and the availability of well-characterized and cost-effective 
production methods. Drug release from these systems is controlled by a variety 
of mechanisms, including drug diffusion, tablet erosion, matrix swelling or a 
combination of these mechanisms. Film-coated and osmogen controlled single 
unit dosage forms have also been studied for modified release applications (Cao 
2004, Zang 2003). 
1.1.4 Multiple unit dosage forms 
The concept of the multiple unit dosage form was introduced in the early 
1950s. These solid oral dosage forms consist of a multiplicity of small discrete 
particulates, which include mini-tablets, pellets and granules (Bodmeier 1994). 
These systems provide flexibility during formulation development and 
therapeutic benefits to patients. A significant advantage of multiparticulates is 
that they can be divided into desired doses without formulation or process 
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changes. They can also be blended to deliver simultaneously incompatible 
bioactive agents or particles with different drug release properties. Furthermore, 
these dosage forms are less susceptible to dose dumping than the reservoir or 
matrix type, single unit tablet since the drug release profile does not depend on 
the drug release properties of a single unit (Erkoboni 2003). 
Pellets offer advantages as constitutes of multiple unit dosage forms since 
studies have indicated that they are rapidly and evenly dispersed in the 
gastrointestinal tract upon oral administration, thus maximizing drug absorption 
and reducing inter- and intra-subject variability due to differences in gastric 
emptying rates (Sandberg 1988). Pellets can be filled into hard gelatin capsules 
or compressed into tablets, which rapidly disintegrate into multiple units.  
1.2 METHODS OF PELLET PREPARATION 
Pharmaceutical pellets or beads are spheres of varying diameter that can 
be produced by several methods. Pellets usually range in size from 0.5-1.5 mm 
depending on the application, but systems have been reported that use pellets as 
large as 3.0 mm (Gandhi 1999). 
1.2.1 Spray drying 
Spay drying is a process in which an aqueous solution of core materials 
and polymer are atomized into hot air. The water evaporates and the dry solids 
separate into pellets. Researchers have noted that this technique produces hollow 
pellets when the liquid evaporates at a rate faster than diffusion of the dissolved 
substances back into the interior of the droplet. Additionally, dissolved 
substances can migrate to the droplet surface as the liquid evaporates, resulting in 
an internal void (Ghebre-Sellassie 1989). 
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1.2.2 Spray congealing 
In spray congealing, a drug is dissolved or dispersed in a molten material 
that is sprayed into an air chamber where the temperature is maintained below 
the melting points of the sprayed materials. This process provides spherical 
congealed pellets (Ghebre-Sellassie 1989). The resulting pellets are held together 
by solid bonds formed from the congealed melts. Furthermore, the particles 
exhibit low porosity due to the absence of solvent evaporation during the spray 
congealing process (Hincal 1994).  
1.2.3 Fluidized bed technology 
Fluidized bed technology suspends a drug and core materials in an air 
stream to form a constantly agitated fluidized bed. Pellets are formed when a 
binder solution, suspension or melt is sprayed onto the fluidized powder bed 
(Wan 1996). However, control of this process is difficult. Wetting, drying, and 
mixing of particles occurs simultaneously in one apparatus. These different 
elementary processes affect each other and thus the influence of each 
phenomenon on the growth kinetics of granulation is difficult to characterize 
(Hemati 2003).  
1.2.4 Layer building 
Another technique used to prepare pellets is layer building. A solution or 
suspension of binder material and drug is sprayed onto the surface of an inert 
core. Multiple layers are often applied to achieve the desired dose. This process 
is efficient since pellets can be coated with a functional polymer in the same 
apparatus after layer building. However, this technique is limited to low dose 
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drugs since only small drug loadings can be effectively layered onto the core 
material (Chambliss 1989). 
1.2.5 Wet-mass extrusion and spheronization 
Wet-mass extrusion and spheronization is a multiple-step process for 
producing uniformly sized pellets. The process requires at least five units of 
operation including dry mixing, wet granulation, extrusion, spheronization and 
drying. After drying, screening may be required to obtain a narrow particle size 
distribution and coating is usually necessary for controlled-release applications. 
The spheronization technique was invented by Nakahara in 1964 
(Nakahara 1966), but it was not widely known until publication of the process by 
employees of Eli Lilly and Co. (Conine 1970, Reynolds 1970). A major 
advantage of this technique over other methods is the ability to achieve a high 
drug loading without producing an excessively large particle (Erkoboni 2003). 
Furthermore, researchers have noted that extrusion/spheronization processes 
usually exhibit high throughput and low wastage of materials (Gandhi 1999). 
1.3 CONTROLLED DRUG RELEASE FROM WET-MASS 
EXTRUDED/SPHERONIZED PELLETS 
Film-coating is widely used to modify the release of active ingredients 
from pellets. Materials that have been studied for the production of controlled-
release coating include waxes, shellac, ethylcellulose, cellulose acetate, acrylic 
resins and silicone elastomers (Porter 2000). Although film-coating is the most 
frequently employed method of producing controlled-release pellets, the process 
is not without problems. This technique is labor intensive and costly since 
coating systems require water or solvent removal, which may include a post-
coating drying or curing step at elevated temperatures. Additionally, drug release 
 6
profiles may not be reproducible due to variations in film-coating thickness 
(Andersson 2000) or imperfections in the coating that result from aging or 
cracking of the polymer film (Lippold 2001). Employing matrix pellet systems to 
control drug release may circumvent problems associated with film-coating 
(Gandhi 1999). 
Cold-mass extrusion and spheronization techniques have been studied to 
produce controlled-release matrix pellets, which utilize an eroding matrix system 
or release retarding agents.  Mehta et al. (2001) manufactured eroding matrix 
pellets using the acrylic polymers Eudragit® L 100-55 and Eudragit® S 100.  
Controlled-release pellets have also been produced using release-modifying 
agents such as hydrophobic components (Ghali 1989), cellulose-derivatives 
(Levis 2001), chitosan (Goskonda 1993) and pH adjusters (Bianchini 1992).  
Nevertheless, many of these systems offer limited control of drug release 
or present processing difficulties. Furthermore, cold-mass extrusion and 
spheronization methods generally utilize water and require an energy demanding 
and time consuming drying phase. Reports have also demonstrated that drug 
release rates from matrix systems depend significantly on the processing 
technique and that matrix systems developed using thermal methods display 
slower drug release rates than systems produced by non-thermal methods (Onay-
Basaran 1985, Billa 1998).  
1.4 THERMAL PRODUCTION TECHNIQUES 
1.4.1 Melt-granulation 
The melt-granulation process is a single-step technique that converts fine 
powders into granules of various sizes. In particular, the powder agglomeration is 
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promoted by the addition of low melting point binders, including glycerides, fatty 
acids, polyethylene glycols and waxes. This process also requires that materials 
are stable at temperatures above the melting range of the binder (Holm 1997). 
Melt-granulation is usually performed in high shear mixers which are 
capable of producing granules and pellets. Researchers have found that high 
shearing forces and long massing times generally promote the formation of near 
spherical pellets (Seo 2001) Heating jackets are usually applied to control the 
product temperature. However, it is difficult to maintain a constant temperature 
since the shearing forces raise the product temperature due to the heat of friction 
(Hamdani 2002). Also, the process is difficult to control since pellet sphericity is 
influenced by several formulation variables, including concentration of the 
binder (Heng 2000), the viscosity of the binder (Heng 2003) and the particle size 
of the binder (Schæfer 1996) and filler (Johansen 2001). 
1.4.2 Melt-extrusion 
In melt-extrusion applications, a drug is dissolved or dispersed in a 
molten binder. Various polymers and low molecular weight excipients such as 
sugars, sugar alcohols and waxes have been employed as thermal binders 
(Breitenbach 2002). This process offers advantages over conventional 
granulation methods since molten binders are employed instead of water or other 
solvents. The raw materials are forced through die to yield a product of uniform 
shape. When the process occurs at elevated temperatures, it is often referred to as 
hot-melt extrusion.  
Melt-extrusion is a well studied method since it is a widely applied 
processing technique used in the plastics industry to produce tubes, pipes, wires 
and films. The intense mixing and agitation during processing cause suspended 
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drug particles to deaggregate in the polymer melt, resulting in a more uniform 
dispersion of fine particles (McGinity 2000). .Melt-extrusion is an efficient and 
continuous process (Liu 2001) that has been studied by pharmaceutical scientists 
to prepare granules, sustained-release tablets and transdermal drug delivery 
systems (Follonier 1994, Aitkin-Nichol 1999, Repka 1999, Zhang 1999, Zhang 
2000). Furthermore, this technology leads itself to comprehensive documentation 
and process controls and thus satisfies regulatory authorities. Pharmaceutical 
products manufactured using melt-extrusion techniques have been approved in 
the USA, Europe and Asia (Breitenbach 2003). 
1.5 MELT-EXTRUSION TECHNOLOGY 
Melt-extrusion processes consist of three basic steps: melting or 
plasticating a solid material, shaping the molten material and solidification of the 
material into a desired shape. Mixing of additives and fillers is an additional 
function of some extrusion processes. Several types of downstream equipment 
are employed to further process the extrudate into the desired form.    
1.5.1 Equipment  
The polymer industry uses several different designs of extruders, but the 
main distinction between various extruders is their mode of operation: 
discontinuous or continuous (Rauwendaal 1994). Discontinuous extruders are 
equipped with a reciprocating member to deliver molten materials in an 
intermittent fashion, while extruders with a continuous mode of operation use a 
rotating member. Injection and blow molding are processes that employ 
discontinuous extruders. Examples of continuous equipment include screw, disk 
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and drum extruders. Most reported pharmaceutical applications of hot-melt 
extrusion have employed screw extruders.  
Screw extruders are divided into single screw and multi screw extruders. 
The single screw extruder is the most important type of extruder used in the 
polymer industry due to its advantages of relatively low cost, straightforward 
design, ruggedness and reliability (Chung 2000). A vertical, single screw 
extruder is seen in Figure 1.1. The screw of conventional single screw extruders 
has three geometrically different sections (Figure 1.2). The first section is 
referred to as the feed section or solid conveying zone. The screw generally has 
deep flights in this zone, and the material in this section will be mostly in the 
solid state. The section closest to the die is called the pumping section or 
metering zone. The pumping action is generated by the shallow flights of the 
screw in this section. Furthermore, thermal material in this zone is in the molten 
state during melt-extrusion applications. The section of the screw that connects 
the conveying zone to the metering zone is called the melting or transition zone. 
Thermal material is melted or plasticated in this section. Additionally, the depth 
of the screw channel reduces in a linear fashion going from the conveying to the 
metering section. This transition in screw flight compresses material in the 
channel.  
A basic function of melt-extrusion applications is shaping of molten 
materials. A die is attached to the end of the extruder barrel that gives shape to 
the final product. The objective of an extrusion die is to distribute the melt in the 
flow channel such that the material exits from the die with a uniform velocity. 
The design of extruder dies is influenced by several variables, including the 
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composition of the extrudate as well as the operating parameters of the extruder 
(Perdikoulias 2003).  
The cross-section of extrudates often increases upon exiting the die due to 
a phenomenon known a die swell. In general, polymers that exhibit low Reynolds 
Number flows swell from 10% to 300% upon exiting the die, and this 
phenomenon depends on material composition, extruder speed, temperature and 
screw speed. This entropy driven event occurs as the individual polymer chains 
recover from the deformation imposed by the rotating screw by “relaxing” and 
increasing their radius of gyration.  
Pelletization is a downstream operation of melt-extrusion processes in 
which molten materials that are pumped through a die are cooled and formed into 
pellets. Pelletizers are available in several different designs, but the resulting 
pellet is generally cylindrical in shape. Examples of strand and die face 
pelletizers are illustrated in Figure 1.3. Strand pelletizers cut a spaghetti-like 
strand using a bed knife and a milling-type rotor. The strands are usually cooled 
by passing through a water bath before being cut. In pharmaceutical applications, 
the cooling bath is often replaced with a cooling belt or static cooling table since 
many pharmaceutical products cannot contact water. Die face pelletization is an 
alternative processing method that cuts the strand at the die face in the molten 
form. The pellet is then cooled via air or liquid (Case 2003). 
1.5.2 Materials used in pharmaceutical applications 
In pharmaceutical applications, melt-extrusion equipment is used to 
disperse or dissolve an active ingredient and other functional excipients in a 
carrier material. Ingredients used to prepare pharmaceutical dosage forms are 
subject to strict purity and safety standards since the products are administered to 
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humans. Thus, most raw materials used in pharmaceutical melt-extrusion 
applications have also been employed in the production of dosage forms by 
conventional techniques (Repka 2000). In addition to these requirements, 
materials used in melt-extrusion applications must exhibit thermal stability 
during processing.  
1.5.2.1 Thermal carriers 
The material in which the drug is dissolved or dispersed is called the 
thermal carrier or binder. During extrusion, the carrier is usually transformed into 
a molten state. This phenomenon is termed melting when the solid material is 
crystalline and plasticating when the material is amorphous. In pharmaceutical 
melt-extrusion processes, the carrier substance is usually a polymer or low 
melting point wax. The heat due to friction generated by the screw is often 
sufficient to melt many low melting point waxes. Modulated differential 
scanning calorimetery (MDSC) and thermal gravimetric analysis (TGA) are often 
used to study the thermal properties of carriers employed in thermal applications.  
The physical and chemical properties of the carrier significantly influence 
the drug release properties of the resulting dosage from. The waster solubility of 
the carrier material is critical when designing a controlled-release product. 
Researchers have found that the mechanism of drug release is primarily diffusion 
controlled from melt-extruded dosage forms containing water insoluble polymers 
and waxes such as ethyl cellulose (Crowley 2004) or carnuba wax (Sato 1997). 
Researchers have also studied systems containing water soluble polymers such as 
hydroxypropyl cellulose (Repka 2002), poly(ethylene oxide) (Zhang 1999) or 
polyvinylpyrrolidone (Follonier 1995) that control drug release by  mechanism 
that is a combination of drug diffusion and matrix erosion. Furthermore, some 
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crosslinked materials such as Carbopol® polymers swell but do not dissolve in 
water. These materials form a three-dimensional structure that control diffusion 
of the active material (Perez-Marcos 1991).  
The influence of medium pH and ionic strength on the solubility 
properties of carrier materials has also been studied. Eudragit® S is an ionic 
polymer based on methacrylic acid esters that exhibits solubility in aqueous 
media ≥ 7. Follonier and coworkers studied this polymer to modulate the release 
of diltiazem hydrochloride from dosage forms prepared using a hot-melt 
extrusion process (Follonier 1995)  
The ionization of polymer networks containing carboxylic or sulphonic 
acid groups occurs as the surrounding medium rises above the pKa of the 
ionizable moiety. Researchers have found that the swelling properties of 
ionizable gels are significantly influenced by both medium pH and ionic strength 
(Khare 1995). This property of ionizable gels can be employed to modify drug 
release rate. Refer to Table 1.1 for a list of carriers that have been used in melt-
extruded dosage forms. 
1.5.2.2 Plasticizers 
A key feature of melt-extruders is their ability to efficiently melt and 
plasticate materials. When polymers are used, a polymer film is generated on the 
inner barrel surface as a result of heat conduction through the barrel. Rotation of 
the screw displaces the melt film and mixes the molten material into the bulk. In 
pharmaceutical applications, plasticizers are typically low molecular weight 
compounds. Researchers have noted that the incorporation of plasticizers into 
pharmaceutical polymers facilitate thermal processing, modify drug release 
properties and improves the surface appearance of dosage forms. Thermal 
 13
processing temperatures and times can often be reduced upon addition of a 
plasticizer, thus diminishing degradation of thermally labile components (Repka 
1999).  
Plasticizers improve the workability and flexibility of polymers by 
reducing the elastic modulus, tensile strength, melt viscosity and glass transition 
temperature (Tg) of the material. Four major theories have been proposed to 
explain the mechanism of plasticization, including the lubricity, gel, salvation-
desolvation and free volume theories. The efficiency of plasticization depends on 
the chemical structure, molecule weight and concentration of the plasticizer. 
Sears and Darby (1982) discussed in detail the theories of polymer/plasticizer 
compatibility. The compatibility of polymers and plasticizers can be indicated by 
various parameters, including internal pressure, solubility parameter, dielectric 
constant and polarity parameter. 
Drugs and other excipients used in pharmaceutical applications can 
sometimes be employed as plasticizers of polymers. Wu and McGinity (1999) 
reported that solid non-traditional plasticizers including methyl paraben and 
drugs such as ibuprofen and chlorpheniramine maleate were able to lower the 
glass transition temperature of polymeric films prepared from aqueous latex 
dispersions of Eudragit® RS 30 D. Zhu and coworkers (2002) studied a melt-
extrusion process to prepare controlled-release tablets containing Eudragit® RS 
PO and chlorpheniramine maleate (CPM). The researchers found that the acrylic 
polymer was plasticized in situ by CPM during thermal processing.  
1.5.2.3 Drugs 
The physical and chemical properties of drugs often limit the formulation 
and processing options available for the development of controlled-release 
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dosage forms. Drugs often exhibit the potential for degradation due to hydrolysis 
when aqueous or hydroalcoholic media are employed during processing. Melt-
extrusion offers benefits over many conventional granulating methods since 
water and other solvents are not required. Additionally, tablets of poorly 
compressible active ingredients that cannot be processed by traditional tableting 
equipment can be prepared by a melt-extrusion (McGinity 2003). However, the 
thermal properties of drugs processed by melt-extrusion are critical since many 
materials are thermally labile. Thus, the thermal stability of drugs used in melt-
extrusion applications should be studied using techniques such as TGA and 
HPLC.  
Met-extrusion forms a solid dispersion of one or more active ingredient in 
inert carrier(s) in the solid state. Solid dispersions can be classified as simple 
eutectics, solid solutions, glass solutions, glass suspensions, a compound or 
complex formation, amorphous precipitations in crystalline carriers or 
combinations thereof (Chiou 1971). Other researchers have defined solid 
dispersions based on drug solubility in the carrier material. When the drug is not 
soluble in the carrier material, the dispersion is termed a particulate dispersion or 
solid suspension. Drugs that exhibit solubility in the thermal carrier are dispersed 
on the molecular level and are called molecular dispersions or solid solutions 
(Dyar 2003).  
Production of solid dispersion has been widely studied to reduce particle 
size and increase rates of dissolution (Bloch 1987). Traditionally, solid solutions 
of drugs have been prepared by melt or solvent evaporation methods. The 
resulting semisolid materials were hardened by cooling, pulverized, sieved, 
mixed with excipients and then filled into tablets or compressed into tablets. 
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These techniques were tedious and difficult to scale up. Melt-extrusion 
techniques are solvent-free and require fewer operations, and thus simplify the 
formation of solid solutions. Researchers used a melt-extrusion process to 
improve the solubility and dissolution rate of 17-estradiol hemihydrate 
(Hülsmann 2000). Polyethylene glycol (PEG) 6000, polyvinylpyrrolidone (PVP) 
and a vinylpyrrolidone-vinylacetate copolymer were used as carrier materials. 
The thermally processed solid dispersions exhibited a significantly increased  
dissolution rate of the drug when compared to physical mixtures of the drug.   
A risk of molecular solid dispersions is conversion of the dissolved drug 
to the crystalline form since drugs usually exhibit limited solubility in polymers. 
However, morphologically stable melt-extruded solid dispersions have been 
prepared with drug loadings up to 60% (Breitenbach 2003). As illustrated in 
Table 1.2, several analytical methods have been employed to study the 
crystallinity of materials in a solid dispersion and to prove the quality and 
stability of the system.  
The molecularly dispersed state of the drug can be stabilized by the 
matrix. Carriers with glass transition temperatures significantly above the storage 
temperature are generally preferred to produce stabile the solid dispersions. 
Additionally, the viscosity of the carrier material and intermolecular interactions 
between the drug and carrier are used to stabilize solid dispersions. Doherty and 
York (1987) studied a dispersion that was formed and stabilized by a hydrogen 
bond—furosemide—PVP interaction.  
1.5.2.4 Functional excipients 
Functional excipients used in melt-extrusion applications are broadly 
classified as release-modifying agents, bulking agents, processing agents and 
 16
miscellaneous additives. The selection and use of these excipients can impart 
specific properties to HME pharmaceuticals in a manner similar to those in 
traditional dosage forms (Zheng 1999, Repka 2000).  
Traditional pharmaceutical excipients have been employed as thickening 
agents for melt-extrusion applications. Cuff and Raouf (1998) studied the 
influence of microcrystalline cellulose on the viscosity of the melt and the 
plasticity of the resulting extrudates of thermally processed matrices containing 
PEG 8000. Although microcrystalline cellulose functioned as a thickening agent, 
the incorporated drug, fenoprofen calcium, prevented hardening of the extrudate.  
Various excipients have been studied to modify drug release rate from 
melt-extruded dosage forms. Follonier and coworkers (1995) found that the low 
porosity of melt-extruded dosage forms can result in incomplete drug release 
during dissolution testing. The researchers employed swelling agents and 
hydrophilic polymers to increase drug release rate by increasing matrix porosity. 
Furthermore, matrix systems often exhibit an initial burst in drug release due to 
solubilization of drug on the surface of the dosage form. The investigators found 
that viscosity inducing agents effectively reduced the observed bust effect.  
Sprockel and coworkers (1997) used a melt-extrusion process to prepare 
disks containing theophylline suspended in polyethylene. Soluble additives were 
studied to increase drug release rate from the dosage forms. The agents studied, 
sucrose, NaCl and Plutonic F68, remained particulate during processing since 
they did not melt at the working temperatures. The studied additives increased 
the rate of theophylline release from the melt-extruded disks. The researchers 
noted that dissolution of the soluble additives increased the void fraction of the 
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matrix and thus increased the probability of forming a percolating pore 
continuous to the disk surface. 
Polymers used as carriers in melt-extruded blends sometimes exhibit 
thermal degradation at the required processing temperatures. Oxidation is the 
primary pathway of degradation observed during melt-extrusion. The thermal 
stability of many materials that are susceptible to degradation can be improved 
with the addition of antioxidants, acid receptors and or light absorbers to the 
processed powder blends (McGinity 2000). Researchers studied the influence of 
antioxidants such as vitamin E and its derivatives, ascorbic acid and butylated 
hydroxyanisole on the thermal degradation of poly(ethylene oxide) during melt-
processing (Crowley 2002), and they found that vitamin E, vitamin E succinate 
and vitamin E TPGS were suitable stabilizers of the polymer during processing. 
Waxy materials such as glyceryl monostearate (GMS) have been studied 
as thermal lubricants during hot-melt extrusion. Henrist and coworkers (1999a, 
1999b) investigated the influence of GMS concentration on the physical 
properties of melt-extrudates of starches and sugar alcohols. The researchers 
found that changing the composition of the formulation did not affect the water 
content or the porosity of the extrudates but that it did significantly influence the 
mechanical strength and dissolution properties of tablets. Furthermore, vitamin E 
TPGS has been reported to facilitate thermal processing by decreasing barrel 
pressure, drive amps, torque and the propensity for degradation of the API and 
other matrix components (Repka 2000). 
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1.6 RESEARCH OUTLINE 
1.6.1 Overall objective 
The overall objective of these studies was to characterize a novel melt-
extrusion and spheronization process and to investigate the influence of thermal 
processing on the physicochemical and drug release properties of melt-extruded 
dosage forms.  
1.6.2 Supporting objectives 
1.6.2.1 Investigate the influence of production methods on the physicochemical 
and drug release properties of matrix beads 
Wet-mass extrusion and spheronization is the more established method of 
producing spherical pellets, but this technique is not without problems since it 
utilizes water and/or other solvents, it is not a continuous processing method and 
it requires additional processing steps such as film-coating to produce controlled-
release systems. Melt-extrusion is an efficient, continuous and solvent-free 
process that has been studied to prepare granules, sustained-release tablets and 
transdermal drug delivery systems. A novel and continuous melt-extrusion 
technique was characterized to manufacture spherical pellets, and the kinetics 
and mechanism of drug release from the resulting beads was examined using 
dissolution investigations and kinetic model fitting procedures. Pellets prepared 
using either wet-mass or melt-extrusion exhibited significantly different drug 
release properties. Thus, the physical characteristics of matrix pellets produced 
using different processing techniques were investigated, including morphology, 
porosity and particle size. The influence of storage conditions on the porosity, 
tortuosity and drug release properties of melt-extruded pellets was also studied. 
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1.6.2.2 Examine the impact of formulation components on processing 
parameters, physical properties and mechanisms of drug release from melt-
extruded dosage forms 
Materials used in melt-extrusion applications must exhibit thermal 
stability during processing. Furthermore, researchers have noted that reduction of 
the melting point or glass transition temperature of the carrier material facilitates 
thermal processing by decreasing barrel pressure, drive amps, torque and the 
propensity for degradation of the API and other matrix components. The 
suitability of formulations for melt-processing was determined using thermal 
gravimetric analysis and modulated differential scanning calorimetry. The 
chemical stability of extruded drugs was also verified using high performance 
liquid chromatography. 
The solid-state solubility of the drug in the carrier material is important to 
consider when developing a solid dispersion since supersaturated systems bear 
the risk of reverting back to the more stable crystalline form, thus creating 
morphologically unstable products. A group contribution method was used to 
calculate the Hansen solubility parameters of materials and to predict 
drug/polymer miscibility. The morphological stability of melt-extruded beads 
was studied using powder X-ray diffraction and scanning electron microscopy.  
Mixtures of polymers and excipients have proved useful in regulating the 
mechanism of drug release from matrix systems. The processability and the 
physicochemical properties of melt-extruded dosage forms based on a premixed 
polymer and excipient blend were investigated. The mechanism and kinetics of 
drug release were investigated using model fitting (Korsmeyer-Peppas, zero-
order, first-order, Hixson-Crowell and Higuchi) and matrix hydration/erosion 
studies. 
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16.2.3 Investigate the influence of compression and film-coating on the 
physical properties, kinetics of drug release and physical aging of thermally 
processed drug delivery systems 
Although marketed controlled-release dosage forms exhibit significant 
differences in the design and composition, these preparations can be broadly 
categorized as single or multiple unit systems. Multiparticulate dosage forms 
offer several advantages, such as improved bioavailability and reduced risks of 
dose dumping, local irritation and tampering.  The influence of compaction on 
the drug release characteristics and physical properties of melt-extruded pellets 
was investigated surface area, porosity and dissolution studies. Furthermore, the 
effect of compression force, filler excipient and pellet to excipient ratio on the 
properties of pellet containing compacts was studied using drug release, 
hardness, friability and disintegration time determinations. 
An advantage of melt-extruded beads over wet-mass extruded systems is 
that thermally processed beads can control drug release without a functional 
coating. However, film-coating is a useful and widely employed method of the 
pharmaceutical industry. Thus, a film-coating process was studied to design a 
melt-extruded pellet system with pH-dependent drug release properties. The 
stability of drug release from coated pellets was determined after storage for 1 
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 CHEMICAL NAME TRADE NAME
Ammonio methacrylate copolymer Eudragit® RS/RL
Poly(dimethylaminoethylmethacrylate-
co-methacrylic esters) Eudragit® E




Poly(methacrylic acid-co-             
methyl methacrylate) 1:2 Eudragit® S
Hydroxypropyl cellulose Klucel®
Ethyl cellulose Ethocel®
Cellulose acetate butyrate CAB 381-0.5
Cellulose Acetate Phthalate --
Poly(ethylene oxide) Polyox® WSR
Poly(ethylene glycol) Carbowax®
Poly(vinyl pyrrolidone) Kollidon®
Poly(vinyl acetate) Sentry® plus
Hydroxypropyl Methylcellulose         
Phthalate --
Polyvinylpyrrolidone-co-              
vinyl acetate Kollidon® VA64
Hydroxypropyl Methylcellulose Methocel®





























Table 1.1: Continued. 
 








Poly(vinyl acetate-co-methacrylic acid) CIBA-I
Epoxy resin containing               
secondary amine CIBA HI
Polycaprolactone --
Carnauba Wax --
Ethylene-vinyl acetate               
copolymer Evatane
®
Glyceryl Palmitostearate Precirol® ATO 5
























































































































































Figure 1.3:  Pelletizers used in melt-extrusion applications. 




Chapter 2: Production of spherical pellets by a novel hot-melt 
extrusion and spheronization process 
 
Reprinted with permission from Young, C.R., Koleng, J.J., and McGinity, J.W. 
International Journal of Pharmaceutics. 2002, 22 (1-2), 87-92. 
 
2.1 INTRODUCTION 
The aim of controlled-release technology is to achieve a predictable and 
reproducible drug release rate over an extended period of time. Controlled-
release delivery systems allow reduced dosing frequency and provide constant 
drug levels in the blood, thus increasing patient compliance and decreasing 
adverse drug events (Berner 1992). Pellets are frequently used in controlled-
release systems because they are freely dispersed in the gastrointestinal tract and 
they offer flexibility for further modification. Wet-mass extrusion and 
spheronization is the more established method of producing spherical pellets, but 
pellets manufactured by this method are usually film-coated to control drug 
release. Researchers have investigated matrix systems produced by extrusion and 
spheronization to control drug release and to avoid difficulties associated with 
film-coating, but many of these systems only offer limited control of drug release 
or present processing difficulties (Gandhi 1999).   
Hot-melt extruded dosage forms are complex mixtures of the active 
ingredient, matrix carrier(s) and functional excipients. These excipients are 
broadly classified as release-modifying agents, bulking agents, processing agents 
and miscellaneous additives. The selection and use of various excipients can 
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impart specific properties to melt-extruded pharmaceuticals in a manner similar 
to those in traditional dosage forms (Zheng 1999; Repka 2000). 
The purpose of this investigation was to characterize a hot-melt extrusion 
(HME) process to manufacture spherical pellets and to examine the controlled 
drug release properties of the spherical pellets produced by the novel thermal 
process. 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
Eudragit® Preparation 4135 F (4135 F) is an acrylic polymer that was 
donated by Röhm GmbH (Darmstadt, Germany). Anhydrous theophylline 
USP/NF was purchased from Spectrum Quality Products, Inc. (Gardena, CA). 
Poly(ethylene glycol) 8000 powder (PEG 8000, NF) was supplied by Dow 
Chemical (Midland, MI), and microcrystalline cellulose (MCC) was provided by 
FMC (Newark, Delaware).     
2.2.2 Spherical pellet production 
The pellet formulation for melt-processing consisted of the thermal 
carrier, 4135 F (48%), anhydrous theophylline (30%) as the model drug, and 
functional excipients including PEG 8000 (7%) and MCC (15%). Eudragit® 
Preparation 4135 F was first ground using a cryogenic grinder since it was 
supplied as large granules. The powders were passed through a 30-mesh (600 
µm) screen and the powder formulation was blended for 5 min at 2000 
revolutions per min (rpm) in a high-shear granulator (Robot Coupe® RSI 3VG; 
Ridgeland, MS) to assure adequate mixing. 
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The dry powder blend was extruded using a Randcastle Microtruder® 
RCP-0750 (Cedar Grove, NJ) vertical, single-screw extruder. The extruder 
temperature controllers were set as follows: Zone 1 = 82°C, Zone 2 = 118°C, 
Zone 3 = 121°C and Die = 121°C. The formulation was fed into the hopper after 
the extruder zones and die had equilibrated to the set temperatures. After exiting 
the cylindrical die, the polymeric strand with a diameter of 1.22 ± 0.03 mm was 
fed into a Randcastle Pelletizer RCP-2.0 and was uniformly cut into cylindrical 
pellets 1.22 ± 0.04 mm in length. The pellets were allowed to cool to room 
temperature under ambient conditions and then a 75 g sample was transferred 
into a Caleva Model 120 Spheronizer (Dorset, England). A Milwaukee™ Model 
1220 (International Tool Corporation; Davie, FL) heat gun was used to facilitate 
pellet deformation by circulating hot air through the product exit of the 
spheronizer. The pellets were marumerized for approximately 45 min at 65-70°C 
and dusted with microcrystalline cellulose to prevent agglomeration during 
processing. The HME pellets exhibited a 1.6% w/w loss on drying after 
lyophilization for 72 h.  The spheronized pellets were packaged in sealed HDPE 
bottles and stored at 25°C/60% RH and 40°C/75% RH. A schematic 
representation of the HME and spheronization process is shown in Figure 2.1. 
2.2.3 Thermal analysis of formulation components and pellets 
Thermal gravimetric analysis (TGA) of pellet formulation components 
was performed with a Perkin Elmer TGA 7 using a heating rate of 10°C/min 
from 50°C to 600°C. The polymer glass transition temperatures (Tg) were 
determined by modulated differential scanning calorimetry (MDSC, TA 
Instruments Model 2920; New Castle, DE) using a heating rate of 5°C/min over a 
temperature range of –20°C to 120°C. 
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2.2.4 Pellet morphology 
The morphology of gold:palladium (60:40, Ted Bench Top Sputter 
Coater) coated HME pellets were examined using a Philips Model 515 Scanning 
Electron Microscope (SEM).  
2.2.5 Dissolution  
Dissolution testing of the theophylline containing pellets was conducted 
using the USP 27 Apparatus 2 (paddle method, VanKel VK6010; Cary, NC) in 
900 mL of medium maintained at 37°C and 100 rpm. The pH 1.0 medium was 
0.1 N HCl, and the pH 3.0, 6.8 and 7.4 media were 50 mM phosphate buffer 
solutions. A VanKel VK8000 auto sampler was used to withdraw 4 mL samples 
at 0.25, 0.5, 1, 2, 4, 6 and 12 h time points. Filtered samples were assayed by UV 
spectrophotometry (DU-65, Beckman Instruments; Fullerton, CA) at 272 nm.  
Dissolution tests were performed in triplicate. 
2.3 RESULTS 
Eudragit® Preparation 4135 F is an experimental copolymer composed of 
methyl acrylate, methacrylic acid and methyl methacrylate. The preparation is 
ideal for colonic delivery systems since it is soluble in aqueous media at pH 7.0 
and above. The copolymer is also an excellent candidate for thermal processing 
since it is flexible and has a low Tg of 49.2°C as experimentally determined by 
MDSC.    
A powder formulation composed of theophylline and 4135 F with 
functional excipients was melt-extruded and spheronized. Functional excipients 
in melt-extruded powder blends may be classified as release-modifying agents, 
bulking agents, processing agents and miscellaneous additives. MCC was chosen 
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as a thermal processing aid for the powder blend used in this study since it acted 
as an anti-tacking agent. PEG 8000 was included in the formulation to facilitate 
HME since it plasticized the 4135 F. The presence of a solid-state plasticizer of 
the acrylic polymer lowered the Tg of the polymer preparation, which allowed 
for lower processing temperatures and shorter processing times. Although the 
experimentally determined Tg of 4135 F was 49.2°C, the experimentally 
determined Tg of the plasticized HME product was 23.1°C. Furthermore, TGA 
demonstrated that the formulation was suitable for HME since the formulation 
components did not experience weight loss at the processing temperatures as 
illustrated in Figure 2.2.    
The SEM micrographs displayed in Figure 2.3 demonstrate the 
differences in the surface morphologies of the beads as a function of 
spheronization time. The HME bead manufactured using a 45 min spheronization 
time exhibits a surface indentation (2.3 A). The indentation on either side of the 
pellet represents the cut edges of the unspheronized pellet. Spheronization rounds 
the pellet ends, thus increasing spheronization time can reduce or eliminate the 
indentation. The spherical pellet in Figure 2.3 B illustrates the elimination of the 
surface indentation with an 80 min spheronization time. However, dissolution 
investigations found no difference between the drug release rates from pellets 
with different spheronization times.  
The melt-extruded and spheronized matrix pellets exhibited control of 
theophylline release as a function of medium pH. The theophylline release 
profiles in pH 1.0 and 3.0 media are similar with both releasing approximately 
52% of the drug after 12 h (Figure 2.4). The drug release profiles of the HME 
beads were characteristic of a diffusion-controlled matrix system. Drug release 
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was governed by solute diffusion within the matrix phase and decreased with 
time due to a receding drug boundary and to a decreasing area at the diffusion 
front. Researchers have noted that matrix systems exhibit negligible or no 
movement of the diffusion front due to swelling or erosion when the matrix 
polymer is insoluble in the dissolution medium (Lee 1992). The matrix polymer, 
4135 F, of the studied HME beads was insoluble in the acidic aqueous media. 
Additionally, Follonier and coworkers noted that porosity is an important 
determinant of drug release from melt-extruded sustained release pellets 
(Follonier 1994; Follonier 1995). Slowed drug release rates from HME beads is 
further explained by decreased free volume since thermal treatment at elevated 
pressures decreases polymer free volume in the bead. Free volume is defined as 
the volume of an amorphous material that is not occupied by molecules of the 
amorphous material. Available free volume in an amorphous material determines 
diffusion of other molecules through the matrix material, thus increased degree 
of packing results in decreased drug release rates (Wicks 1986). When the HME 
spherical pellets were tested in pH 6.8 medium, approximately 69% of the 
theophylline was released after 12 h (Figure 2.4).  Theophylline release increased 
in pH 6.8 medium because it was close to the pH at which the polymer starts to 
dissolve. Complete theophylline release was attained in approximately 4 h when 
the HME beads were tested in pH 7.4 medium. Drug release behavior in pH 6.8 
and 7.4 was diffusion-controlled, but polymer swelling and dissolution also 
influenced drug release. The early stage of the dissolution process is dominated 
by polymer swelling as the polymer changes from a glassy to a rubbery state due 
to water penetration and subsequent plasticization. Dissolution of the polymer 
occurs when the water concentration at the polymer surface exceeds a critical 
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concentration of macromolecular disentanglement (Lee 1992). HME beads 
remained intact after dissolution testing for 12 h in pH 1.0, 3.0 and 6.8 media. 
The matrix beads did not disintegrate in these media due to matrix polymer 
insolubility and to significant polymer chain entanglement in the core matrix. 
The HME beads completely dissolved after dissolution testing for approximately 
4 h at pH 7.4, where the matrix polymer was soluble. 
Although the Tg of the HME product was 23.1°C as determined by 
MDSC, the pellets exhibited no sticking after storage for 1 week in sealed HPDE 
containers at 40°C/75% RH. Furthermore, theophylline release properties of the 
HME beads did not change after storage for 1 year in sealed HDPE containers at 
25°C/60% RH as demonstrated in Figure 2.5. 
2.4 DISCUSSION 
The findings from this study demonstrated that controlled-release 
spherical matrix pellets could be successfully prepared using a HME and 
spheronization process. Melt-extruded matrix pellets exhibited diffusion-
controlled drug release. Drug release from the acrylic matrix system studied was 
influenced by the pH of the dissolution medium since the solubility of the matrix 
polymer, Eudragit® Preparation 4135 F, is pH dependent.   
HME pellets are a unique dosage form because they can be used for 
immediate release or controlled-release applications depending on the properties 
of the matrix polymer. Conventional pellets must be coated to prevent rapid drug 
release, even when an insoluble matrix is employed. HME pellets do not require 
film-coating to control drug release, but they can be film-coated to further 
modify drug release in the gastrointestinal tract. Although our study employed 
Eudragit® Preparation 4135 F to produce spherical pellets, other polymers and 
 41
thermal agents are currently under investigation to demonstrate the versatility of 
this melt-extrusion and spheronization process. 
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Figure 2.2: Thermal gravimetric analysis of pellet formulation components. 
Key: A. PEG 8000; B. Theophylline; C. Microcrystalline Cellulose; D. 








































Figure 2.3:  SEM micrographs of spherical pellets (approximately 1.2 mm 
diameter).   
Key: A. Spherical pellet produced by HME after spheronization for 45 

























































Figure 2.4: Influence of medium pH on the release of theophylline from pellets 
produced by HME and spheronization (USP 27 Apparatus 2, 900 
mL, 37°C, 100 rpm, n = 3).   



































Figure 2.5: Effect of 1 year storage at 25°C/60% RH on the release of 
theophylline from hot-melt extruded and spheronized pellets (USP 
27 Apparatus 2, 900 mL, 37°C, 100 rpm, n = 3).   





Chapter 3: Properties of drug-containing spherical pellets 
produced by a hot-melt extrusion and spheronization process 
 
Reprinted with permission from Young, C.R., Koleng, J.J., and McGinity, J.W. 
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3.1 INTRODUCTION 
Recent advances in controlled-release technology have allowed the 
development of drug delivery systems that permit less frequent dosing and 
provide constant blood levels of active pharmaceutical ingredients (API). 
Controlled-release dosage forms increase patient compliance and minimize 
adverse drug events (Berner 1992). Although there are significant formulation 
differences among various controlled-release dosage forms, these preparations 
can be broadly categorized as either single or multiple unit systems.   
Multiple unit dosage forms such as pellets offer advantages as 
constituents of controlled-release systems. Pellets are rapidly and evenly 
dispersed in the gastrointestinal tract upon oral administration, thus maximizing 
drug absorption and reducing inter- and intra-subject variability due to 
differences in gastric emptying rates (Vergote 2001). Furthermore, pellets offer 
flexibility for further modification, such as film-coating or compression into 
multiparticulate tablets. Betageri et al. (1995) described methods of 
manufacturing controlled-release pellets, which included coating drug-containing 
pellets with a polymer or placing the drug in an insoluble or eroding bead matrix.   
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Many researchers have demonstrated the effectiveness of film-coating in 
controlling drug release (Porter 2000). Although film-coating is a conventional 
method of producing controlled-release pellets, the process is not without 
problems. This technique is labor intensive and costly since coating systems 
require water or solvent removal, which may include a post-coating drying or 
curing step at elevated temperatures. Additionally, drug release profiles may not 
be reproducible due to variations in film-coating thickness (Andersson 2000) or 
imperfections in the coating that result from aging or cracking of the polymer 
film (Lippold 2001). Employing matrix pellet systems to control drug release 
may circumvent problems associated with film-coating (Gandhi 1999). Cold-
mass extrusion and spheronization techniques have been used to produce 
controlled-release matrix pellets, which utilize an eroding matrix system or 
release retarding agents.  Mehta and coworkers (2001) manufactured eroding 
matrix pellets using the acrylic polymers Eudragit® L 100-55 and Eudragit® S 
100.  Controlled-release pellets have also been produced using release-modifying 
agents such as hydrophobic components (Ghali 1989), cellulose-derivatives 
(Levis 2001), chitosan (Goskonda 1993) and pH adjusters (Bianchini 1992).  
Nevertheless, many of these systems offer limited control of drug release 
or present processing difficulties. Additionally, cold-mass extrusion and 
spheronization methods generally utilize water and require an energy demanding 
and time consuming drying phase. Earlier reports have also demonstrated that 
drug release rates from matrix systems depend significantly on the processing 
technique and that matrix systems developed using thermal methods display 
slower drug release rates than systems produced by non-thermal methods (Onay-
Basaran 1985, Billa 1998).   
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Hot-melt extrusion (HME) is a thermal processing method that offers 
advantages over conventional granulation methods since molten binders are 
employed instead of water. HME generates a product of uniform shape by 
forcing materials through a die under controlled conditions. HME is an efficient, 
continuous and solvent-free process (Liu 2001) that has been applied in the 
pharmaceutical field to prepare granules, sustained-release tablets and 
transdermal drug delivery systems (Follonier 1994, Aitkin-Nichol 1999, Repka 
1999, Zhang 1999, Zhang 2000). Furthermore, intense mixing and agitation 
during HME processing cause suspended drug particles to deaggregate in the 
polymer melt, resulting in a more uniform dispersion of fine particles (McGinity 
2000).  
Thus, a melt-extrusion process would offer advantages as a method for 
spherical pellet production. The objectives of the present study were to 
investigate physical characteristics of pellets produced by either wet-mass 
extrusion or HME and to study the mechanisms of drug release from matrix 
pellets.  Properties investigated included particle size distribution, morphology, 
porosity and dissolution characteristics. 
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
Eudragit® Preparation 4135 F (4135 F) was donated by Röhm GmbH 
(Darmstadt, Germany). Anhydrous theophylline USP/NF was purchased from 
Spectrum Quality Products, Inc. (Gardena, CA). Poly(ethylene glycol) 8000 
(PEG 8000, Carbowax® 8000) powder was supplied by Dow Chemical (Midland, 
MI), and microcrystalline cellulose (MCC, Avicel® PH-101) was donated by 
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FMC (Newark, Delaware). All materials were used as received from the supplier 
except where noted.    
3.2.2 Spherical pellet production 
The pellet formulation consisted of the polymer 4135 F (48%), 
theophylline (30%), polyethylene glycol 8000 (7%) and microcrystalline 
cellulose (15%). Eudragit® Preparation 4135 F was received as granules, but 
polymer particle size was reduced to a fine powder using a Micron Powder 
System model CF cryogenic grinder (Summit, NJ). Formulation components 
were passed though a 30-mesh (600 µm) screen and then blended for 5 min at 
2000 revolutions per min (rpm) in a Robot Coupe® RSI 3VG high-shear 
granulator (Ridgeland, MS). The powder blend was then processed by either wet-
mass extrusion and spheronization or HME and spheronization. 
For the sample processed by conventional wet-mass extrusion and 
spheronization, approximately 15% w/w water was added to the dry powder 
blend before the damp mass was cold-mass extruded using a LCI bench top 
granulator (Tokyo, Japan) equipped with a 1.0 mm screen. The extruded granules 
were transferred into a Caleva 120 spheronizer (Dorset, England) and 
spheronized for 2.5 min. The pellets were dried at 25°C/60% RH for 24 h, and 
the 14-16-mesh size (1.40-1.18 mm) fraction was collected for further testing.  
For the sample processed by HME, the powder blend was extruded using 
a Randcastle Microtruder® RCP-0750 (Cedar Grove, NJ) single-screw extruder. 
The extruder temperature controllers were set as follows:  Zone 1 = 82°C, Zone 2 
= 118°C, Zone 3 = 121°C and Die = 121°C. A cylindrical die 1.2 mm in diameter 
was used. After exiting the die, the polymeric strand, exhibiting a diameter of 
1.22 ± 0.03 mm, was fed into a Randcastle RCP-2.0 pelletizer and uniformly cut 
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into cylindrical pellets 1.22 ± 0.04 mm in length. The pellets were cooled to 
ambient temperature, and a 75 g sample was transferred into a Caleva Model 120 
spheronizer. A Milwaukee™ Model 1220 (International Tool Corporation; 
Davie, FL) heat gun was used to control the temperature of the spheronizer bowl 
at 60-70°C since the pellets did not deform when spheronized at ambient 
temperature. The pellets were spheronized for 45 min, and the 14-16-mesh size 
(1.40-1.18 mm) fraction was collected for further testing.  
3.2.3 Pellet morphology and particle size distribution 
The surface and cross-sectional morphologies of spherical pellets 
produced by wet-mass extrusion and HME were examined using a Hitachi S-
4500 field emission scanning electron microscope (Rolling Meadows, IL). The 
particle size distribution of a 200 g sample was determined by shaking for 15 min 
with USA standard testing sieves (Arthur H. Thomas Company; Philadelphia, 
PA). 
3.2.4 Thermal analysis of pellets 
The thermal properties of Eudragit® Preparation 4135 F and the processed 
pellets were characterized using modulated differential scanning calorimetry 
(MDSC, Model 2920, TA Instruments, New Castle, DE). Samples of 
approximately 10 mg were accurately weighed and hermetically sealed in 
aluminum pans. The samples were analyzed under a nitrogen atmosphere at a 
heating rate of 3°C per min over the temperature range of –20°C to 120°C. 
Modulation was set at +/- 1°C every 60 s. The reported glass transition 
temperature (Tg) was the midpoint of the integrated first heating cycle transition. 
MDSC analysis of samples was performed in triplicate. 
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3.2.5 Dissolution 
Dissolution testing of the theophylline-containing pellets was conducted 
using the USP 27 Apparatus 2 dissolution method (Paddle Method, VanKel 
VK6010; Cary, NC) in 900 mL of media maintained at 37°C with a paddle 
agitation rate of 100 rpm. The pH 1.0 medium was 0.1 N HCl, while the pH 3.0, 
6.8 and 7.4 media were 50 mM phosphate buffered solutions. A VanKel VK8000 
auto sampler was used to withdraw 4 mL samples at 0.25, 0.5, 1, 2, 4, 6 and 12 h 
time points.  
In addition to conventional dissolution studies, USP 27 Apparatus 3 
dissolution testing (Reciprocating Cylinder Method, VanKel Bio-Dis II; Cary, 
NC) was performed in 250 mL of media at 37°C and 20 dips per min (dpm). The 
media evaluated included pH 1.0 (0.1 N HCl), 3.0, 5.0, 6.8 and 7.4 (50 mM 
phosphate buffer). The theophylline-containing beads transited though multiple 
media, including 2 h in pH 1.0, 1 h in pH 3.0, 5.0 and 6.8, and 3 h in pH 7.4. 
Apparatus 1 and 2 dissolution tests were performed in triplicate, and complete 
drug release was determined after the final sample time point by high-speed 
agitation of the dissolution vessel contents for 2.5 min with a Polytron® 
homogenizer (Brinkmann Instruments; Westbury, NY). Filtered dissolution 
samples were assayed by UV spectrophotometry at 272 nm.  
3.2.6 X-ray diffraction 
Powder X-ray diffraction profiles of formulation components and HME 
pellets were obtained using a Philips PW 170 X-ray generator equipped with a 
PW 1710 X-ray diffractometer. The operating current and voltage were 40 mA 
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and 40 kV, respectively. Samples were examined using a 2-theta scanning range 
from 5° to 50° at a scanning rate of 2° per min. 
3.2.7 Porosity  
 
Pellet porosity measurements were calculated using equation 3.1 for 
percent effective porosity (Varner 1991, Andreola 2000):   
 
 
%ε = [(ρt – ρb) / ρb] x 100                     (Eq. 3.1) 
 
where ε = effective porosity, ρt = true density and ρb = bulk density. The true 
density of the powder formulation was determined in triplicate using He 
pycnometry (Micrometrics® AccuPyc 1330 pycnometer; Norcross, GA) to 
measure the density of the powder formulation prior to processing. Hg 
porosimetry (Micrometrics® PoreSizer 9320; Norcross, GA) was employed to 
determine the bulk densities of spherical pellets, in triplicate, after processing. 
Water was removed from powders and pellets by lyophilization for 72 h prior to 
density determinations.  
3.3 RESULTS AND DISCUSSION 
The current study used thermal processing to prepare pellets containing 
Eudragit® Preparation 4135 F, an experimental copolymer composed of methyl 
acrylate, methacrylic acid and methyl methacrylate. This material has potential 
applications for colonic delivery systems since the polymer is soluble in aqueous 
media at pH 7.0 and above. Eudragit® Preparation 4135 F is flexible and has a 
low glass transition temperature (Tg), making this material an excellent candidate 
for thermal processing.  
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A powder blend containing theophylline, 4135 F, MCC and PEG 8000 
was melt-extruded and then spheronized. MCC was included in the formulation 
as a massing aid during cold-mass extrusion and as an anti-tacking agent during 
thermal processing. PEG 8000 was included as a plasticizer to facilitate HME 
processing. The presence of a solid-state plasticizer further lowered the Tg of the 
acrylic polymer preparation, which allowed for lower processing temperatures 
and shorter processing times. Reduction of these parameters diminishes the 
propensity for degradation of thermally labile components (Repka 1999). The 
experimentally determined Tg of 4135 F was 50.3 ± 0.5°C, whereas the Tg of the 
plasticized, melt-extruded product was 24.8 ± 1.3°C.  
The SEM micrographs in Figure 3.1 illustrate the morphological features 
of bead surfaces at low magnification. The HME bead (3.1 B) exhibited a surface 
indentation, although no granular characteristics were observed as noted with 
beads produced by wet-mass extrusion (3.1 A). The indentation on the HME 
bead represents the cut surface of the unspheronized granule. Melt-extruded 
pellets were spheronized for 45 min, and pellet surface morphology was visually 
examined at 5 min intervals. The surface indentation was reduced or eliminated 
with increasing spheronization time. Dissolution studies found no difference 
between the drug release rates from pellets after spheronization for 5 min. A 
significant advantage of spherical pellets is in film-coating and compression 
applications. 
The particle size distributions of beads produced by wet-mass extrusion 
and HME are represented in Figure 3.2. The mesh size number indicates the 
screen opening size, which decreases as the mesh size number increases. 
Approximately 90% of the HME beads were of size 14-16-mesh (1.40-1.18 mm), 
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while only 50% of the wet-mass extruded beads were in this size range. Thus, 
HME processing yielded a narrower particle size distribution since HME pellet 
particle size is a function of spherical orifice diameter of the extruder die and the 
rate of pelletization. Production of beads with a narrow particle size distribution 
is desired for controlled-release products (Wheatley 1997, Chopra 2002) and for 
applications such a film-coating (Rubio 1994).  
The HME beads exhibited controlled theophylline release in all 
dissolution media tested with the exception of pH 7.4, while the wet-mass 
extruded beads exhibited rapid release in all dissolution media studied. As seen 
in Figure 3.3, wet-mass beads exhibited complete theophylline dissolution after 
approximately 4 h in pH 1.0 medium, whereas only 52% drug release was 
observed after 12 h in the same medium for HME beads. The dissolution profiles 
of wet-mass extruded and HME pellets in pH 1.0, 3.0, 6.8 and 7.4 media are 
summarized in Table 3.1 as the time point when at least 50% theophylline was 
released. Dissolution results for HME pellets in pH 1.0 and 3.0 media were 
similar, but a faster theophylline release rate was observed in buffered medium 
pH 6.8. The drug release rate from the HME pellets increased in this medium 
since the pH was near 7.0, the value at which the polymer is soluble. The 
dissolution results indicate that both wet-mass extruded and HME exhibited rapid 
drug release in pH 7.4 medium.  
Higuchi (1961) developed a mathematical model for the release 
properties of ointment bases containing drugs in suspension. In 1963, Higuchi 
used this equation to explain the release properties of solid drug particles 
dispersed in solid matrices. The theoretical analysis considered the mechanism of 
drug release from both homogeneous and heterogeneous solid matrix systems.  
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Drug release from a homogenous matrix is due to medicament diffusion through 
the enveloping matrix, whereas release from a heterogeneous or granular matrix 
is the result of drug leaching as dissolution medium penetrates the matrix through 
pores, cracks and intragranular spaces. The Higuchi model describes drug release 
from planar systems, where the percentage of drug released is proportional to the 
square root of time. An equation was later derived by Baker and Lonsdale that is 
based on the Higuchi model, but describes drug diffusion from a spherical 
matrix. This equation has been used to model release data from several 
formulations of microcapsules and microspheres (Costa 2001, Zhang 1999): 
 
 
(3/2)[1 – (1 – (Mt/M∞))2/3] – (Mt/M∞) = t(3DCsε)/(r2Coτ) (Eq. 3.2) 
 
In equation 3.2, Mt/M∞ is the fraction of drug released from the matrix at time t, 
D is the diffusivity of the drug in the dissolution medium, Cs is the solubility of 
the drug in the surrounding medium, Co is the initial drug concentration in the 
matrix and r is the radius of the spherical system. The porosity and tortuosity of 
the matrix are represented by ε and τ, respectively.  
As seen in Figure 3.4, theophylline release from the HME pellets was 
predominately diffusion-controlled in media below pH 7.4 as described by the 
Baker-Lonsdale model.  The r2 values for Apparatus 2 dissolution profiles in pH 
1.0, 3.0 and 6.8 media were 0.9974, 0.9968 and 0.9899, respectively. Dissolution 
time points plotted represented less than 85% theophylline released. This model 
describes a diffusion-controlled drug release mechanism from an inert granular 
matrix when the matrix does not erode or dissolve over time. Drug release rate 
from HME pellets in pH 7.4 medium was not adequately described by the Baker-
Lonsdale model (r2 = 0.9469) since the matrix polymer is soluble in aqueous 
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media pH > 7.0.  Thus, drug release behavior from the HME pellets in pH 7.4 
medium was a result of both drug diffusion and matrix dissolution.  
The USP paddle method (Apparatus 2) was employed to replicate transit 
through the human gastrointestinal tract. As illustrated in Figure 3.5, the wet-
mass extruded beads exhibited rapid and complete theophylline release. In 
contrast, the HME beads displayed slower and more controlled drug release. At 
the 5 h time point, which included 1 h in pH 6.8, only 35% of the theophylline 
dose was released. The remaining theophylline was completely dissolved in the 
pH 7.4 medium within 3 h. Thus, the HME beads exhibited greater retardation of 
theophylline release than the wet-mass beads when using both the paddle and the 
reciprocating cylinder methods to quantify drug release.     
The morphologies of formulation components were studied to further 
explain the drug release results from both the wet-granulated and the melt-
extruded pellets. The dissolution rate of an API can depend on the morphology of 
the compound, with amorphous forms typically exhibiting faster dissolution rates 
than crystalline structures. Since thermal processing may alter the crystalline 
nature of matrix systems, the crystallinity of pellets was determined. Similar X-
ray diffraction profiles were observed for pellets manufactured by both wet-mass 
extrusion and HME (Figure 3.6), which demonstrates that the crystallinity of the 
matrix system did not change significantly after thermal processing. Thus, 
changes in crystallinity did not account for differences in drug release rates from 
the two pellet types.  
Furthermore, the high pressures employed during HME may have 
decreased the free-volume of the resulting extrudates, thus reducing the 
dissolution rate of theophylline from the melt-extruded pellets. Free-volume of 
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an amorphous material is defined as the volume that is not occupied by 
molecules of the material (Wicks 1986). Transport of materials in a closely 
packed system depends primarily on the degree of entanglement, or free-volume 
of the system, thus a matrix system with a low free-volume exhibits a slow drug 
release rate since the matrix network inhibits drug diffusion (Struik 1978). 
Porous dosage forms usually exhibit faster drug release rates since these 
systems have more channels for water to enter and to dissolve the drug (Tongwen 
1998). The effective porosity describes the space occupied by air inside a dosage 
form prior to the dissolution of the drug. Effective porosities of the wet-mass 
extruded and HME pellets, calculated using He pycnometry and Hg porosimetry 
determinations, were found to be significantly different (n = 3, student t-test, p < 
0.0005 at α = 0.05). The porosity of the wet-mass extruded beads was 6.09 ± 
0.08%, whereas the porosity of the HME beads was 3.70 ± 0.08%. In addition to 
differences in porosity, researchers have also used the theory of tortuosity to 
explain slower release from thermally processed matrix systems since studies 
have indicated that thermal processing results in a more tortuous product (Foster 
1990, Zang 2001). Tortuosity describes the directness of the path from the 
surface of the pellet to a void in the pellet. The pathway is more convoluted in a 
system with high tortuosity, making drug diffusion though the matrix pores more 
difficult.  
Electron microscopy was used to qualitatively study the effect of the 
processing method on pellet porosity. The micrograph in Figure 3.7 represents 
the cross-sectional view of pellets at high magnification. Distinct drug and 
excipient particles are visible in the wet-mass extruded bead (3.7 A), while the 
HME bead (3.7 B) exhibited a less porous matrix. Drug and excipient particles 
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are more completely enclosed in the thermally processed composite due to 
interactions between solid particles and molten polymer chains (Foster 1990). 
Dispersed particles illustrated in the HME matrix are theophylline or MCC since 
these materials are not soluble in Eudragit® Preparation 4135 F under the studied 
processing conditions.  
Researchers have employed post-processing thermal treatment of matrix 
systems to decrease drug release rate. Omelczuk and McGinity (1993) reported 
that thermal treatment of tablets containing PLGA above the Tg of the polymer 
significantly retarded drug release by promoting distribution of the polymer 
throughout the matrix and ensuring complete coalescence of the matrix polymer.  
Furthermore, Billa et al. (1998) found that thermal treatment of Eudragit® NE 
40D containing matrix tablets reduced the rate of drug release due to formation 
of a matrix with higher tortuosity and lower porosity. Dissolution properties of 
HME and wet-mass extruded pellets were studied after storage for 24 h at 40°C 
or 60°C.  Pellets were equilibrated for 24 h at 25°C/60 RH prior to dissolution 
testing. Dissolution profiles of heat-treated pellets were compared to the profiles 
of untreated pellets using a model independent approach to calculate difference 
(f1) and similarity (f2) factors (Guidance 1997). Generally, dissolution curves are 
considered equivalent when f1 values are less than 15 and f2 values are greater 
than 50. The comparison factors seen in Table 3.2 demonstrate that post-
processing thermal treatment did not significantly influence theophylline release 
rate from either wet-mass extruded or HME pellets. Thus, curing had minimal 




Spherical pellets were successfully manufactured by a HME and 
spheronization process. HME and spheronization is a continuous process and 
does not require a lengthy drying step due to the absence of water or other 
solvents during manufacturing. Melt-extruded pellets exhibited a narrower 
particle size distribution in comparison with pellets prepared by conventional 
wet-mass extrusion. When the same dry powder formulation was employed, 
HME beads released theophylline more slowly than wet-mass extruded beads. 
Theoretical analysis of dissolution profiles indicated that theophylline release 
from HME pellets was a diffusion-controlled process as described by the Higuchi 
diffusion mode, and the drug release rates from HME pellets were not affected 
by the curing conditions studied. Furthermore, wet-granulated pellets did not 
exhibit diffusion-controlled drug release even after post-processing thermal 
treatment.    
HME pellets can be employed in multitude of pharmaceutical 
applications since drug release rate is controlled by the properties of the matrix 
polymer. Conventional pellets must be coated to prevent rapid drug release, even 
when an insoluble matrix is used. Although HME pellets do not require a coating 
layer to prevent rapid drug release, melt-extruded pellets can be additionally 
modulated to further control drug release in the gastrointestinal tract. 
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Table 3.1: The time point when at least 50% theophylline was released from wet-
mass extruded and HME pellets in various dissolution media (USP 


















Table 3.2: Dissolution profile comparisons of wet-mass extruded and HME 








Factor 40°C 60°C 40°C 60°C
f1 2 3 2 2
























Figure 3.1: Low-magnification SEM micrographs of the surface of spherical 
pellets produced by two different techniques (approximately 1.2 
mm diameter).  
Key: A. Pellet produced by wet-mass extrusion and spheronization; B. 

































Figure 3.2: Particle size distribution of spherical pellets produced by two 
different techniques as determined by sieve analysis.  








































Figure 3.3: Dissolution in pH 1.0 medium of pellets prepared by two different 
techniques (USP 27 Apparatus 2, 900 mL, 37°C, 100 rpm, n = 3). 






































































Figure 3.4: Baker-Lonsdale diffusion model fitting of theophylline release data 
from HME pellets, where b = (3/2)[1 – (1 – (Mt/M∞))2/3]. (USP 27 
Apparatus 2, 900 mL, 37°C, 100 rpm, n = 3).  
Key:  pH 1.0, r2 = 0.9974;  pH 3.0, r2 = 0.9968; ▲ pH 6.8, r2 = 
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Figure 3.5: Influence of media pH on the release of theophylline from pellets 
produced by two different techniques (USP 27 Apparatus 3, 250 
mL, 37°C, 20 dpm, n = 3).  






















































Figure 3.6: X-ray diffraction profiles of pellets manufactured by different 
processing methods. 






















Figure 3.7: High-magnification SEM micrographs of the cross-section of pellets 
produced by two different techniques (approximately 1.2 mm 
diameter).  
Key: A. Cross-section of pellet produced by wet-mass extrusion and 





Chapter 4: Compression of controlled-release pellets produced by 
a hot-melt extrusion and spheronization process 
 
Manuscript in review, Pharmaceutical Development and Technology. 
 
4.1 INTRODUCTION 
Conventional drug therapy involves the periodic dosing of a therapeutic 
agent that has been formulated to ensure stability, activity and bioavailability of 
the active pharmaceutical ingredient (API). Nevertheless, many drugs present 
difficulties when administered by conventional methods due to toxicity and low 
therapeutic index problems. Controlled-release systems have been designed to 
maintain plasma drug levels in the therapeutic range and thus minimize the 
effects of such problems (Sood 2003). Furthermore, controlled-release systems 
reduce dosing frequency, thereby improving patient compliance and therapeutic 
efficacy (Sinha 2002). Although there are significant differences in the design 
and composition of marketed controlled-release dosage forms, these preparations 
can be broadly categorized as either single or multiple unit dosage forms. 
The monolithic matrix-based tablet is an example of a single unit delivery 
system. The concept of the multiple unit dosage form was introduced in the early 
1950s. These solid oral dosage forms consist of a multiplicity of small discrete 
particulates or pellets. Each unit exhibits desired drug release characteristics, and 
the pellets act together to provide the overall drug release profile. Thus, this 
system is less susceptible to dose dumping than the reservoir or matrix type, 
single unit dosage forms (Gandhi 1999). The individual elements are often 
granules or coated crystals.  
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Pellets offer advantages as constitutes of controlled-release systems since 
pellets are rapidly and evenly dispersed in the gastrointestinal tract upon oral 
administration, thus maximizing drug absorption and reducing inter- and intra-
subject variability due to differences in gastric emptying rates (Sandberg 1988). 
Pellets can be filled into hard gelatin capsules or compressed into tablets, which 
rapidly disintegrate into multiple units. This dosage form is less susceptible to 
dose dumping than the reservoir or matrix type, single unit tablet since the drug 
release profile does not depend on the drug release properties of a single system 
(Erkoboni 2003). Additionally, multiparticulate tablets provide dosing flexibility 
since they can be scored and divided without compromising controlled-release 
properties of the individual units.  
Nevertheless, the use of pellets as a dosage form is not without 
disadvantages. Wet-mass extrusion and spheronization, also termed cold-mass 
extrusion and spheronization, is the most frequently used method of producing 
spherical pellets. This process utilizes a granulating liquid such as water. The 
API can be included in the extruded pellet formulation or added onto the surface 
of non-pareil pellets. Drug-layering of non-pareil pellets employs the use of a 
binder solution, which is usually water based, to promote adhesion of the API 
onto the pellet surface. Thus, wet-mass extrusion and drug-layering require 
energy demanding and time consuming drying phases. Many drugs also exhibit 
stability problems due to the presence of water during processing and residual 
water during storage. Furthermore, pellets produced using these methods 
generally exhibit rapid drug release and require a film-coating to provide 
controlled-release properties, and coatings can be damaged during the tableting 
process.  
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A novel hot-melt extrusion (HME) and spheronization process was 
recently reported to produce spherical pellets without the use of water or other 
solvents (Young 2003). This method eliminates drug instability problems during 
processing due to water and ameliorates health, safety and environmental 
concerns due to solvents. Furthermore, pellets produced by melt-extrusion do not 
require an additional film-coating since drug release is diffusion controlled.  
The aim of the current study was to investigate the physicomechanical 
and dissolution properties of tablets containing controlled-release pellets 
prepared by a HME and spheronization process. The effect of compression force 
on porosity and surface area was also studied. Furthermore, the influences of 
compression force, pellet to excipient ratio and filler excipient selection on the 
properties of pellet containing compacts was investigated using drug release, 
hardness, friability and disintegration time determinations.  
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Eudragit® Preparation 4135 F (4135 F) is an experimental acrylic 
polymer that was donated by Röhm GmbH (Darmstadt, Germany). Anhydrous 
theophylline, USP was purchased from Spectrum Chemical (crystal shape and 
dimensions: needle, 80-100 µm x 100-400 µm; Gardena, CA). Polyethylene 
glycol 8000 powder (PEG, Carbowax® 8000) was supplied by Dow Chemical 
(Midland, MI). Povidone (PVP, Kollidon® 30) and sodium starch glycolate 
(Explotab®) were supplied by BASF (Mount Olive, NJ) and Penwest (Patterson, 
NY), respectively. Soy polysaccharides (Emcosoy®) was donated by Penwest 
(Patterson, NY), modified food starch (CerestarPharm® DC 93000) by Cerestar 
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(Hammond, IN), microcrystalline cellulose (MCC, Avicel® PH-102) by FMC 
(Newark, DE) and the 75:25 mixture of alpha-lactose monohydrate and 
microcrystalline cellulose (Microcelac® 100) by Meggle GmbH (Wasserburg, 
Germany). All materials were passed through a 30-mesh (600 µm) screen prior to 
processing.    
4.2.2 Pellet and tablet production 
The pellet formulation contained the thermal carrier 4135 F (48%), 
theophylline (30%), PEG 8000 (7%) and MCC (15%). The particle size of 4135 
F granules was reduced to a fine powder (90% < 100µm) using a Micron Powder 
System Model CF cryogenic grinder (Summit, NJ). The formulation was mixed 
for 10 min in a twin-shell blender prior to melt-extrusion (Blend Master®, 
Patterson-Kelley, Stroudsberg, PA).  
The powder blend was processed using a Randcastle Microtruder® RCP-
0750 (Cedar Grove, NJ) single-screw extruder. The extruder temperatures 
employed were Zone 1 = 82°C, Zone 2 = 118°C, Zone 3 = 121°C and Die = 
121°C. A cylindrical die 1.2 mm in diameter was used, and the extrudate was 
uniformly cut into cylindrical pellets using a Randcastle RCP-2.0 pelletizer. The 
pellets were marumerized for 15 min in a Caleva Model 120 spheronizer. A 
Milwaukee™ Model 1220 (International Tool Corporation; Davie, FL) heat gun 
was used to elevate the temperature of the spheronizer bowl to 60-70°C. The 14-
16-mesh size (1.40-1.18 mm) pellets were used for compression studies. A 
detailed description of the HME and spheronization process was reported earlier 
(Young 2002). 
Tablets weighing 500 mg were compressed using a Carver Model M 
laboratory press (Wabash, NJ) equipped with a 10 mm concave die. Pellets and 
excipient mixtures were weighed separately and then physically mixed prior to 
compression at 5, 10, 15 and 20 kN. The tableting excipient mixtures consisted 
of 92% filler (MCC, alpha-lactose monohydrate:MCC, modified food starch or 
soy polysaccharides), 5% PVP and 3% sodium starch glycolate. 
4.2.3 Effective porosity measurements 
Pellet porosity measurements were calculated using the following 
equation for percent effective porosity (Varner 1991, Andreola 2000):   
 
 
                                                                                           
                                                           (Eq. 4.1) 
(ρt – ρb) x 100      
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%ε  = ρb 
where ε = effective porosity, ρt = true density and ρb = bulk density. The true 
density of pellets cryogenically ground into fine powder was determined in 
triplicate using helium pycnometry (Micrometrics® AccuPyc 1330 pycnometer; 
Norcross, GA). Mercury porosimetry (Micrometrics® PoreSizer 9320; Norcross, 
GA) was employed to determine the bulk density of spherical pellets, in 
triplicate. Samples were stored at 25°C with desiccants under vacuum for 72 h 
prior to porosimetry and pycnometry determinations. Measurements were 
performed in triplicate.  
4.2.4 Surface area determinations 
The specific surface area was measured using a NOVA-2000 Version 
6.11 instrument equipped with NOVA Enhanced Data Reduction Software 
Version 2.13 (Quantachrome Corporation; Boynton Beach, FL). A known 
amount of pellets (~300 mg) was transferred into a Quantachrome sample cell 
and degassed for at least 3 h prior to analysis. 
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4.2.5 Tablet characterization 
Disintegration times were determined using an Erweka GmbH 
(Heusenstamm, Germany) disintegration tester with a dip rate of 20 dpm in 0.1 N 
HCl medium maintained at 37°C (n = 6), and tablet hardness was measured using 
a Heberlein (Switzerland) hardness tester (n = 6). A VanKel (Cary, NC) 
friabilator was used to determine tablet friability of a 6.5 g sample of tablets (n = 
13).  All experiments were performed according to USP 27 testing guidelines. 
4.2.6 In vitro drug release studies 
Dissolution testing of the theophylline containing pellets and tablets was 
conducted using the USP 27 Apparatus 3 dissolution testing guidelines 
(Reciprocating Cylinder Method, VanKel Bio-Dis II; Cary, NC) in 250 mL of 
medium at 37°C and 20 dpm. The media evaluated included pH 1.0 (0.1 N HCl), 
3.0, 5.0, 6.8 and 7.4 (50 mM phosphate buffered solutions). The tablets transited 
through multiple media, including 2 h in pH 1.0, 1 h in pH 3.0, 5.0 and 6.8, and 3 
h in pH 7.4. Dissolution studies on each formulation were performed in triplicate. 
Dissolution samples were analyzed for theophylline content according to 
the USP 27 method using a Waters® HPLC system equipped with a photodiode 
array detector (Model 996) extracting at 281 nm. The column used was an 
Alltech Inertsil™ ODS-3 3 µm, 150 x 4.6 mm. The mobile phase contained a 
mixture of water:acetonitrile:glacial acetic acid in the volume ratios of 845:150:5 
and 1.156 g/L of sodium acetate trihydrate. The flow rate was 1.5 mL/min, and 
the retention time of the theophylline was 3.6 min.  Linearity was demonstrated 
from 1 to 100 mg/mL (r2 ≥ 0.998), and injection repeatability was 1% relative 
standard deviation for 6 injections.  
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4.3 RESULTS AND DISCUSSION 
4.3.1 Influence of compression force 
We recently reported that theophylline release from 4135 F containing 
HME pellets was predominately diffusion-controlled in media below pH 7.4 
according to the Higuchi model, while the drug release rate was a result of both 
drug diffusion and matrix dissolution in pH 7.4 medium (Young 2003). The 
effective porosity and surface area are critical properties that influence the 
dissolution rate of drugs from controlled-release systems. Furthermore, previous 
workers have found that the surface area and porosity of wet-mass extruded 
pellets can be influenced by compression (Kühl 2002, Johansson 1995, Tunón 
2001), and investigators have employed these measurements as indicators of 
compression-induced changes in drug release rate (Bechard 1992). Thus, tablets 
compressed using 50% pellets and MCC as the filler excipient were disintegrated 
in the dry state by shaking on metal sieves, and the pellets were studied using He 
porosity, Hg porosimetry and BET analysis. Light microscopy photographs of 
spheronized pellets before and after compaction at 20 kN are illustrated in Figure 
4.1. The pellet effective porosity and surface area measurements were not 
influenced by compression force (Table 4.1, n = 3, one-way ANOVA, α = 0.05). 
Thus, compression of molten materials during thermal extrusion prevented 
further densification of pellets during tableting.  
Compression of pellets can either result in a disintegrating tablet that 
breaks into multiparticulates or a matrix tablet resulting from the fusion of film 
coatings. The effect of force on the properties of compacts containing 50% 
pellets and MCC is presented in Table 4.2. Tablet hardness increased with 
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compaction force, and forces of 15 and 20 kN produced tablets with hardness 
values exceeding the scale of the testing equipment. The disintegration times 
increased significantly with compression force, however, all tablets disintegrated 
without fusion of individual pellets. The 5 kN tablet disintegrated in 6 s, whereas 
the 20 kN tablet disintegrated after approximately 1 h. Nevertheless, tablet 
friability did not significantly change for compacts compressed at 10 to 20 kN, 
and only the 5 kN tablets demonstrated a friability value greater than 1%. The 
USP 27 considers a maximum weight loss of not more than 1% to be acceptable 
for most tablet formulations.  
 A significant challenge of tableting film-coated pellets is production of a 
multiparticulate dosage form without changing the drug release properties of the 
individual pellets (Bechard 1992, Flament 1994). The formation of a matrix 
tablet during compression due to fusion of polymer coated pellets usually results 
in a slower drug release rate. Even if the tablet disintegrates into 
multiparticulates, the film coatings could fracture during compression, 
accelerating the drug release rate (Sarisuta 1994). Thus, the influence of 
compaction force on the drug release rate of thermally processed pellets was 
investigated. The dissolution properties of tablets compressed with multiple 
forces and MCC as the filler excipient are shown in Figure 4.2. The rate of 
theophylline release in pH 3.0, 5.0, 6.8 and 7.4 media was identical for the 
compressed and uncompressed pellets, however, drug release in the 0.1 N HCl 
medium was influenced by compression force at 20 kN. The initial lag in 
theophylline release rate was due extension of the disintegration time to 
approximately 1 h which resulted from formation of strong compacts at high 
compression forces.  
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4.3.2 Influence of pellet to filler excipient ratio 
The ratio of pellet to filler excipient has an important role in protecting 
pellets during compression (Bodmeier 1997). Filler excipients aid tablet 
compaction and are used to prevent direct contact between the pellets. Wagner 
and co-workers reported that based on theoretical calculations, a tablet 
formulation must contain at least 29% excipients to fill the void spaces between 
densely packed spheres. Coated pellets are more likely to be damaged and exhibit 
increased drug release rates as the content of filler excipients decreases (Wagner 
2000). The influence of filler excipient content drug release properties was 
investigated in the current study by compressing tablets containing 50, 75 and 
85% pellets. Compacts were produced using 5, 10, 15 and 20 kN of force and 
MCC as the filler excipient. 
 The dissolution and physical properties of compacts are illustrated in 
Table 4.3. Dissolution profiles were compared using a model independent 
approach to calculate difference and similarity factors, also known as f1 and f2 
values. Generally, dissolution curves are considered equivalent when f1 values 
are less than 15 and f2 values are greater than 50 (Guidance 1997). Unlike many 
film-coated formulations, the dissolution rate of theophylline from compacts was 
not influenced by pellet content, even when high compression forces were 
employed. In all cases, the melt-extruded pellets did not fuse during compression 
as a result of pellet to pellet contact. However, tablets containing more than 50% 
pellets exhibited significant friability regardless of compression force. This 
finding was due to the poor compressibility of the dense HME pellets. 
Furthermore, previous researchers have noted decreased hardness and increased 
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friability of compacts containing high percentages of film-coated pellets 
produced by a non-thermal technique (Beckert 1996). 
4.3.3 Influence of filler excipient properties 
Excipients can protect multiparticulates during compression, and previous 
researchers have reported significantly different cushioning effects depending on 
the particle size and compaction properties of the excipient. Torrado and 
Augsburger (1994) studied the influence of excipients on the drug release rate of 
granules coated with Eudragit® RS. They found the order of least film damage to 
be: polyethylene glycol 3350 < microcrystalline cellulose < crospovidone < 
lactose < dicalcium phosphate. Previous investigators have produced pellets 
using soft materials to enhance compactability and cushioning effects 
(Nicklasson 1999, Lundqvist 1998). Vergote and coworkers (2002) found that 
wax beads functioned as a cushioning agent and provided protection to the film-
coatings during compression. However, the dissolution rate of tablets formulated 
with waxy beads was too slow due to the poor disintegration properties of the 
tablets. Thus, protecting film-coated pellets during compression remains a 
significant problem. 
In the current study, the influence of excipient selection on the drug 
release rate of theophylline from melt-extruded pellets was investigated by 
compressing tablets containing 50% pellets and four different filler excipients. 
The materials studied included MCC (Avicel® PH-102), a 75:25 mixture of 
alpha-lactose monohydrate:MCC (Microcelac® 100), modified food starch 
(CerestarPharm® DC 93000) and soy polysaccharides (Emcosoy®). Each 
excipient and pellet mixture was compressed at 5, 10, 15 and 20 kN of force. 
None of the excipient and compression force combinations significantly 
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influenced the drug release rate in the pH 3.0, 5.0, 6.8 or 7.4 media. High 
compression forces of MCC and alpha-lactose:MCC containing compacts 
exhibited delayed drug release in the 0.1 N HCl medium due to extended 
disintegration times caused by formation of strong compacts at high compression 
forces. The drug release profiles were identical to those of uncompressed pellets 
after transition to the pH 3.0 medium. The influence of the filler excipient on 
theophylline release from tableted pellets using a compression force of 15 kN is 
illustrated in Figure 4.3. Only the formulation employing the alpha-lactose 
monohydrate:MCC mixture as the filler excipient exhibited slow tablet 
disintegration. Thus, only the dissolution profile in acid of compressed HME 
pellets was significantly influenced by filler excipient selection.  
4.4 CONCLUSIONS 
Melt-extruded pellets containing Eudragit® Preparation 4135 F were 
found to be an ideal substrate for compression into tablets since compression 
force, pellet to excipient ratio and filler excipient selection did not influence the 
theophylline release rate from rapidly disintegrating compacts. Furthermore, 
tableting did not influence the effective porosity or surface area of pellets since 
compression of molten materials during thermal extrusion produces dense 
extrudates. These findings represent a significant advantage of HME matrix 
pellets over film-coated pellets which are frequently damaged during 
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Table 4.1: Influence of compression force on properties of pellets from compacts containing 50% pellets and 









HME Pellets 5 kN 10 kN 15 kN 20 kN
Surface Area (m2/g) * 0.256 ± 0.02 0.264 ± 0.02 0.262 ± 0.03 0.266 ± 0.02 0.270 ± 0.03
% Effective Porosity * 3.70 ± 0.08 3.72 ± 0.09 3.67 ± 0.05 3.68 ± 0.10 3.65 ± 0.11












Table 4.2: Influence of compression force on tablet properties using a 
formulation of 50% pellets and MCC as the filler excipient 










ardness (Kg) 5.3 ± 0.9 14.5 ± 1.5 >16 >16
isintegration Time (Min) 0.09 ± 0.02 1.37 ± 0.05 18.6 ± 3.2 53.4 ± 3.5













Table 4.3: Influence of compression force and pellet content on tablet properties 
using MCC as the filler excipient (Dissolution, n = 3; Hardness and 








CONTENT 5 kN 10 kN 15 kN 20 kN
     f1 0.9 1.1 1.6 1.5
     f2 93.8 94.5 86.0 82.7
     HARDNESS (Kg) 5.30 14.5 >16 >16
     DISINTEGRATION TIME (Min) 0.09 1.37 18.60 53.40
     FRIABILITY (% Weight Loss) 1.22 0.08 0.07 0.07
     f1 2.0 1.7 1.4 1.5
     f2 82.6 82.4 89.4 87.2
     HARDNESS (Kg) 3.75 11 >16 >16
     DISINTEGRATION TIME (Min) 0.32 0.82 1.47 1.73
     FRIABILITY (% Weight Loss) 28.48 20.73 9.50 4.79
     f1 1.1 0.8 1.2 2.2
     f2 93.9 96.7 86.1 79.6
     HARDNESS (Kg) 3.00 7.5 >16 >16
     DISINTEGRATION TIME (Min) 0.96 1.64 2.69 2.29


































Figure 4.1: Light microscopy photographs of HME and spheronized pellets 
(approximately 1.2 mm diameter pellets at 10x magnification) 
before and after compression with 20 kN of force.  





































Figure 4.2: The influence of compression force on the theophylline release 
profile of compressed HME pellets using 50% pellet content and 
MCC as the filler excipient (USP 27 Apparatus 3, 250 mL, 37°C, 20 
dpm, n = 3).  




































Figure 4.3: The influence of filler excipient selection on the theophylline release 
profile of compacts using 50% pellet content and 15 kN as the 
compression force (USP 27 Apparatus 3, 250 mL, 37°C, 20 dpm, n 
= 3).  
Key:   MCC;  Alpha-lactose monohydrate:MCC, 75:25; ▲ Modified 
food starch;  Soy polysaccharides. 
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Chapter 5: Physicochemical properties and film-coating of a   
melt-extruded and spheronized solid dispersion for                     
pH-dependent drug delivery 
 
5.1 INTRODUCTION 
Controlled drug release systems offer several advantages over 
conventional drug therapies that involve periodic dosing of therapeutic agents. 
Drug delivery systems have been designed to maintain plasma drug levels in the 
therapeutic range and thus minimize toxicity and narrow therapeutic index 
problems (Sood 2003). Controlled release dosage forms can also improve patient 
compliance and therapeutic efficacy by reducing dosing frequency (Sinha 2002). 
Beads have been widely studied as controlled release dosage forms since they 
can be film coated with functional polymers to sustain, delay or target drug 
release. Furthermore, pellets can be delivered in hard gelatin capsules or tablets 
for controlled drug delivery applications. A novel hot-melt extrusion (HME) and 
spheronization process was recently reported to produce controlled release beads 
without the need for film-coating (Young 2002, Young 2003). 
Poly(ethylene oxide) is a semi-crystalline, high molecular weight, water-
soluble polymer which is used in sustained-release applications, oral suspensions 
and suppositories due to its swelling and mucoadhesive properties. The long 
linear chain structure of the polymer forms a strong interpenetrating network 
with mucus. Previous researchers have investigated the properties of bioadhesive 
films and matrix tablets containing poly(ethylene oxide) produced by melt-
extrusion (Zhang 1999, Repka 2000, Crowley 2002), but thermally processed 
bead systems have not been studied. Furthermore, film-coating applications have 
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not been investigated to control drug release from melt-extruded matrix systems 
containing a low melting point thermoplastic carrier.  
The purpose of the current study was to investigate the physicochemical 
properties of poly(ethylene oxide) beads produced by a novel melt-extrusion 
process and film-coated with a pH-dependent polymer. The calculated solubility 
parameters and thermal properties of materials were used to determine the 
suitability of systems for melt-extrusion. Following thermal processing, the 
influence of accelerated storage conditions on the drug release and 
physiochemical properties of pellets was studied. Furthermore, film-coating of 
melt-extruded beads with Eudragit® L 30 D-55 was studied to design a pellet 
system with pH-dependent drug release properties. 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Guaifenesin was purchased from Spectrum Laboratory Products 
(Gardena, CA). Poly(ethylene oxide) (PEO; Polyox™ WSR-301, Mw. 
4,000,000) and ethylcellulose (Ethocel® 100FP Premium) were kindly donated 
by the Dow Chemical Company (Midland, MI). Glyceryl monostearate (GMS; 
Imwitor® 491) was contributed by Sasol (Witten, Germany). Eudragit® L 30 D-
55 and triethyl citrate (TEC) were donated by Röhm (Darmstadt, Germany) and 
Morflex (Greensboro, NC), respectively. HPLC solvents were purchased from 
EM Science (Gibbstown, NJ).    
5.2.2 Calculation of solubility parameters 
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The Hansen solubility parameters of guaifenesin and PEO were 
calculated from the chemical structures using the group contribution method 
described by Van Krevelen and Hoftyzer (Van Krevelen 1990). 
 
δt2 = δd2 + δp2 + δh2     (Eq. 5.1) 
δd = (Σ Fdi) / V      (Eq. 5.2) 
δp = (Σ Fpi2)1/2 / V      (Eq. 5.3) 
δh = [(Σ Ehi) / V] 1/2          (Eq. 5.4) 
 
where,  δt = Total solubility parameter  
 δd = Contribution of dispersion forces 
 δp = Contribution of polar forces   
 δh = Contribution of hydrogen bonding           
            Fdi = Molar attraction constant due to dispersion component           
 Fpi = Molar attraction constant due to polar component           
 Ehi = Hydrogen bonding energy            
  V = Molar volume      
 
For the polymeric excipient, determination of the solubility parameters 
was based on the average molecular weight of 4,000,000. The units of the 
reported solubility parameters are MPa1/2, where 1 MPa1/2 is equivalent to 0.4888 
(cal·cm−3)1/2. 
5.2.3 Thermal analysis 
Thermal gravimetric analysis (TGA) of pellet formulation components 
and blends was performed with a Perkin Elmer TGA 7 using a heating rate of 
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10°C/min from 50°C to 600°C.  The melting points of individual components 
and physical blends were determined by modulated differential scanning 
calorimetry (MDSC, TA Instruments Model 2920; New Castle, DE) using a 
heating rate of 5°C/min over a temperature range of –20°C to 165°C. The 
reported melting point was determined from the second heating cycle. Volatiles 
were removed from samples by storing powders under vacuum with desiccants at 
25°C for 72 h prior to thermal studies. MDSC analysis of samples was performed 
in triplicate. 
5.2.4 Spherical pellet production 
Pellet formulations containing guaifenesin, PEO, ethylcellulose and GMS 
are detailed in Table 5.1. The blends were prepared by geometric dilution, 
introduced into a V-blender (Blend Master®, Patterson-Kelley, East Stroudsburg, 
PA) and mixed for 15 min.  The powders (500 g) were fed into a single-screw 
Randcastle Microtruder® (Model RCP-0750, Cedar Grove, NJ) equipped with a 
Nitralloy 135M screw (3:1 compression ratio with flight configuration containing 
feed, compression and mixing sections) and a 1.5 mm cylindrical die.  Screw 
speed was maintained at 15 rpm.  The three heating zones and die temperatures 
were equilibrated to 60, 75, 85 and 95°C, respectively.  Residence time of the 
materials in the extruder was approximately 5 min.  
The extrudates were uniformly cut into cylindrical pellets using a 
Randcastle RCP-2.0 pelletizer and then merumerized for 15 min in a Caleva 
Model 120 spheronizer. A Milwaukee™ Model 1220 (International Tool 
Corporation; Davie, FL) heat gun was used to elevate the temperature of the 
spheronizer bowl to 60-70°C. Spherical pellets were stored in sealed HDPE 
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containers with silica desiccants at 40°C/75% RH. Beads produced by this novel 
HME and spheronization process are illustrated in Figure 5.1. 
5.2.5 Film-coating 
A 30% (w/w) dispersion of Eudragit® L 30 D-55 was diluted to 15% 
(w/w) solids content based on dry polymer weight. TEC, 15% (w/w) based on the 
dry polymer content, was added to the polymeric dispersion and stirred for 
30 min. Talc, 50% (w/w) based on dry polymer weight, was dispersed in water 
using a Polytron® mixer (Brinkmann Instruments, Westbury, NY) and then 
combined with the plasticized Eudragit® L 30D-55 prior to coating. 
The coating dispersion was applied to a 250 g charge of HME beads 
using a Strea 1 fluidized bed coater (Strea I, Niro Inc., Columbia, MD) with 
bottom spray and a Wurster column insert. The coating conditions were as 
follows: inlet temperature 40°C, outlet temperature 32-34°C, spray rate 4 g/min, 
nozzle diameter 1 mm and atomization pressure 1.75 bar. The coated pellets were 
cured at 40°C for 24 h and then stored at 40°C/75% RH in sealed HDPE 
containers with silica desiccants. 
5.2.6 In vitro drug release studies 
Dissolution testing of uncoated beads was conducted using USP 27 
Apparatus 2 (paddle method) guidelines (Van Kel VK7000; Cary, NC) in 900 
mL of 0.1 N HCl maintained at 37°C and agitated at 100 rpm.  The enteric 
properties of coated products were studied according to Method A, which 
included 2 h in an acidic stage (pH 1.0, 0.1 N HCl, 750 mL) followed by testing 
in a buffered stage (pH 6.8) upon the addition of 250 mL of 0.2 M sodium 
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phosphate tribasic. Pellets stored at accelerated conditions were equilibrated at 
25°C for 24 h before dissolution investigations. 
Dissolution samples were analyzed for guaifenesin content using a 
Waters® HPLC system equipped with a photodiode array detector (Model 996) 
extracting at 276 nm. The data were collected and integrated using Empower® 
Version 5.0 software.  The column used for guaifenesin analysis was an Alltech 
Alltima™ C18 10 µm, 250 x 4.1 mm.  The mobile phase contained a mixture of 
water:methanol:glacial acetic acid in volume ratios of 600:400:15. Solvents were 
vacuum filtered though a 0.45 µm nylon membrane and degassed using a Waters 
In-Line Degasser AF. The flow rate was 1.5 mL/min, and the retention time of 
guaifenesin was 3.0 min.  Linearity was demonstrated from 2 to 200 mg/µL (r2 ≥ 
0.998), and injection repeatability was 0.35% relative standard deviation for 10 
injections.  
5.2.7 Weight loss on drying 
The amount of volatiles in pellet samples was determined gravimetrically 
using the USP 27 method for weight loss on drying of guaifenesin. Samples 
weighing approximately 2 g were dried at 60°C under a vacuum with desiccants 
for 5 days. The dried pellets were equilibrated at 25°C under a vacuum with 
desiccants for 24 h before reweighing.  
5.2.8 Tortuosity and effective porosity measurements 
The tortuosity and bulk density of pellets were determined using an 
AutoPore IV 9500 mercury intrusion porosimeter (Micromeritics, Norcross, GA). 
Approximately 3 g of pellets were placed in a 5 cc bulb penetrometer, and 
pressure was applied from 1 to 15,000 psia. The technique for measuring 
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tortuosity using mercury porosimetry was previously described by Crowley et al. 
(Crowley 2004). 
Pellet porosity measurements were calculated using equation 1 for 
percent effective porosity (Varner 1991, Andreola 2000):   
 
% ε = [(ρt – ρb) / ρb] x 100      (Eq. 5.5)  
                                                                                                 
where ε = effective porosity, ρt = true density and ρb = bulk density. The true 
density of pellets cryogenically ground into fine powder was determined using 
helium pycnometry (Micrometrics® AccuPyc 1330 pycnometer; Norcross, GA). 
Samples were stored at 25°C with desiccants under vacuum for 72 h prior to 
porosimetry and pycnometry determinations. Measurements were performed in 
triplicate. 
5.2.9 Scanning electron microscopy 
The surface morphology of gold:palladium (60:40, Ted Bench Top 
Sputter Coater; Redding, CA) coated beads was examined using a Hitachi S-
4500 field emission scanning electron microscope (Rolling Meadows, IL).  
5.2.10 Powder X-ray diffraction 
The crystalline properties of formulation components and melt-extruded 
pellets were examined using a Philips PW 170 X-ray generator equipped with a 
PW 1710 X-ray diffractometer. The operating current and voltage were 40 mA 
and 40 kV, respectively. Samples were examined using a 2-theta scanning range 
from 5° to 55°, a step size of 0.05° and a dwell time of 1 s. 
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5.3 RESULTS AND DISCUSSION 
5.3.1 Calculation of solubility parameters 
Previous researchers have demonstrated the potential of melt-extrusion to 
form solid dispersions (Gruenhagen 1996, Breitenbach 2002, Forster 2001). The 
advantages of using melt-extrusion over solvent-based systems to form molecular 
solid dispersions include absence of residual solvents, decreased environmental 
implications, decreased costs and the possibility of continuous processing 
(Gruenhagen 1996). Molecular solid dispersions are defined as a molecular 
embedding in a carrier that is a glass or crystalline matrix (Breitenbach 2003).  
Ideally, drugs processed to form molecular solid dispersions should 
exhibit unlimited solubility in the carrier, but this is rarely the case and 
supersaturated systems are often produced. These dispersions bear the risk of 
reverting back to the more stable crystalline form, thus creating morphologically 
unstable products. Thus, the solid-state solubility of the drug in the carrier 
material is important to consider when developing a solid dispersion. Calculation 
of solubility parameters has been employed by several researchers to predict the 
miscibility of drugs and excipinets (Suzuki 1997, Greenhalgh 1999, Hancock 
1997).  
Currently, the most widely accepted group contribution method for 
calculation of solubility parameters is the three component system developed by 
Charles Hansen, which divides the total Hildebrand value into: a dispersion force 
component, a hydrogen bonding component and a polar component (van 
Krevelen 1990). Compounds with similar total solubility parameters (δt) are 
likely to be miscible since the energy of mixing from intramolecular interactions 
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is balanced with the energy of mixing from intermolecular interactions. 
Greenhalgh and coworkers (1999) used the difference between the total solubility 
parameters (∆δt) of materials to estimate miscibility, concluding that that 
compounds with ∆δt < 7 MPa1/2 were likely to be miscible and that compounds 
with ∆δt > 10 MPa1/2 were likely to be immiscible. The solubility parameters 
calculated using the group contribution method as described by Van Krevelen 
and Hoftyzer (Van Krevelen 1990) are seen in Table 5.2. Guaifenesin and PEO 
are likely to exhibit partial or complete miscibility since the ∆δt is 2.99 MPa1/2. 
5.3.2 Thermal studies 
The thermal properties of materials and powder blends were studied to 
determine drug/polymer miscibility and processing parameters. Extrusion 
temperature is critical due to the potential thermal instability of formulation 
components during processing. The MDSC thermograms of pure guaifenesin, 
PEO and melt-extruded blends of the materials are shown in Figure 5.2. 
Although guaifenesin alone was characterized by a strong melting transition at 
82.6°C, the transition was not detected in the extrudates containing PEO.  The 
absence of a guaifenesin melting point after co-extrusion with PEO suggested 
miscibility of the blend and supported the prediction of the calculated solubility 
parameters. 
 The melting point of a material is dependent upon the crystal lattice of 
the solid. Impurities in a material break up the regular, repeating molecular 
pattern of the crystal lattice and thus result in broadening of the melting range 
and depression of the melting point (Vogel 1996).  Introduction of guaifenesin 
broadened the melting range and decreased the melting point of PEO. 
Furthermore, the thermograms exhibited depression of the melting transition with 
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increasing guaifenesin concentration. Several researchers have noted that 
reduction of the melting point or glass transition temperature of the carrier 
material facilitates thermal processing by decreasing barrel pressure, drive amps, 
torque and the propensity for degradation of the API and other matrix 
components (Repka 2000, Crowley 2002, Zhu 2002).  
The thermal stability of materials was studied using TGA and HPLC. As 
illustrated in Figure 5.3, TGA was employed to determine the temperature at 
which weight loss due to degradation was observed for individual formulation 
components and physical blends. Guaifenesin exhibited weight loss at 
approximately 200°C, which was well below the processing temperatures of 60 
to 95°C. Furthermore, the chemical stability of guaifenesin after melt-extrusion 
was verified using a stability indicating reversed-phase HPLC method. Thus, the 
drug and formulation components were thermally stable at the processing 
conditions. 
5.3.3 Drug release properties and physical stability of pellets 
PEO hydrates to form a gel layer upon contact with an aqueous medium 
due to strong hydrogen bonding between the polyether chains of the polymer and 
water molecules. The hydrogel erodes as the polymer dissolves. Thus, drug 
release form PEO matrices is controlled by a combination of polymer swelling, 
erosion and drug diffusion through the hydrated gel (Di Colo 2001). Melt-
processed pellets were stored in sealed HDPE containers with silica desiccants at 
40°C/75% RH. The results of drug release investigations of pellets containing 
PEO, guaifenesin and GMS (formulation 1) are illustrated in Figure 5.4. The 
dissolution profiles of the stored pellets were compared to that of the unstored 
beads using a model independent approach to calculate difference and similarity 
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factors, also known as f1 and f2 values. Dissolution curves are considered 
equivalent when f1 values are less than 15 and f2 values are greater than 50 
(Guidance 1997). The f1 values calculated for the dissolution profiles of the 1 and 
3 month samples were 11.1 and 14.7, while the f2 values were 33.1 and 25.7, 
respectively. Thus, guaifenesin release rate decreased after as the 1 and 3 month 
accelerated stability studies since the similarity factors were not greater than 50.  
Despite changes in the dissolution profile, the water content of pellets 
was not significantly influenced by the storage conditions as the pellets were 
stored in sealed HDPE containers with silica desiccants. The initial pellets 
exhibited a weight loss on drying of 0.51 ± 0.06%, while the weight loss on 
drying of beads stored for 1 or 3 months at 40°C/75% RH was 0.46 ± 0.08 and 
0.48 ± 0.06%, respectively.  
Stabilization of the drug release properties of polymeric matrices is 
challenging since such systems frequently exhibit changes in dimensional 
structure upon storage that can significantly decrease the drug release rate. This 
phenomenon is most frequently observed at storage conditions near or above the 
glass transition temperature of the matrix material, where stress relaxation and 
orientation of polymer chains is rapid (Omelczuk 1993).  
Effective porosity is the space occupied by air inside a dosage form prior 
to drug dissolution, and porous systems usually exhibit faster drug release since 
there are more channels for water to enter and to dissolve the API. Tortuosity 
describes the directness of a path from the surface of a dosage form to an internal 
void. Diffusion pathways are more convoluted in systems with high tortuosity, 
thus hindering drug diffusion though the matrix pores. Several researchers have 
noted that decreases in drug release rate upon storage corresponded with 
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decreases in porosity and/or increases in tortuosity (Rubio 1994, Zhang 2001, 
Crowley 2002). The HME pellets containing guaifenesin and PEO did not exhibit 
changes in porosity or tortuosity as demonstrated in Table 5.3. These results are 
in line with the findings of previous researchers who have noted that melt-
extruded matrix dosage forms do not exhibit significant changes in matrix 
structure upon storage since compression and intense mixing of molten materials 
during processing results in a product with low free volume (Kidokoro 2001). 
Product crystallinity was studied to determine the morphological stability 
of the system. As seen in Figure 5.5, SEM analysis of pellet surfaces revealed 
crystal growth upon storage at accelerated conditions. Crystals were not visible 
initially on the pellet surface after thermal processing, but crystal growth 
increased with storage time as more significant morphological changes were 
observed with the 3 month sample. Additional studies were conducted to 
determine which formulation components recrystallized.  
The X-ray diffraction profiles of the pellet components, physical blend 
and processed pellets are seen in Figure 5.6.  The physical blend of materials 
exhibited crystallinity peaks characteristic of PEO at the 2-theta angles 19.1 and 
23.4, while guaifenesin peaks were detected at 12.1, 13.6 and 20.8. After thermal 
processing, only the PEO peaks at 19.1 and 23.4 remained, but the peak intensity 
was significantly reduced. These findings indicated that guaifenesin existed as a 
solid solution or a solid amorphous embedding in the semi-crystalline carrier 
polymer. The intensity of the PEO peaks increased upon storage, and guaifenesin 
recrystallized as peaks were detected at the 2-theta angles 12.1, 13.6 and 20.8 in 
the 3 month stability sample. Thus, PEO crystallinity increased and guaifenesin 
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recrystallized upon storage at 40°C/75% RH in sealed HDPE containers with 
silica desiccants. 
In addition to crystallization of PEO and guaifenesin, the adhesion 
behavior of HME beads changed after storage at accelerated conditions. During 
the initial dissolution investigations, melt-extruded pellets adhered individually 
to the wall of the glass dissolution vessels. The stability samples did not stick or 
agglomerate during storage, but the beads adhered to form a single mass during 
dissolution testing. This phenomenon explains the observed decrease in drug 
release rate after storage since the agglomerated pellets exhibited a reduced 
surface area to volume ratio when compared to the individual pellets. Previous 
researchers have noted that matrix geometry can significantly influence drug 
release rate from systems containing swellable polymers (Katzhendler 1997, 
Siepmann 2000). 
Ethylcellulose is a water-insoluble excipient which controls drug release 
rate by modifying the size and length of diffusion pathways of matrix systems 
(Katikaneni 1995). The influence of ethylcellulose on the drug release properties 
of guaifenesin and PEO containing matrix pellets is illustrated in Figure 5.7. The 
percentage of guaifenesin released after dissolution testing for 1 h in pH 6.8 
medium was reduced from 80 to 60% upon the addition of 15% ethylcellulose 
(formulation 2). Furthermore, the drug release properties of the pellets were 
stable after storage for 1 and 3 months at accelerated conditions. Although 
ethylcellulose containing pellets also exhibited recrystallization of guaifenesin 
and PEO during storage as detected by SEM and X-ray diffraction studies, the 
adhesion behavior of beads during dissolution testing did not change. The initial 
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and stored pellets agglomerated to form a single mass during dissolution 
investigations. 
5.3.4 Film-coating of melt-extruded pellets 
Eudragit® L 30 D-55 is an anionic copolymer of methacrylic acid and 
methacrylates used for enteric drug delivery applications since it solubilizes in 
aqueous media above pH 5.5. Thermally extruded pellets containing PEO, 
guaifenesin and GMS (formulation 1) were film-coated with 5, 10, 15 or 20% 
polymer weight gain, and sticking problems were not observed during processing 
despite the low melting point of the guaifenesin/PEO dispersion. Figure 5.8 
shows that the process was efficient since all coating levels released less than 
10% guaifenesin after 2 h in 0.1 N HCl, with no drug release detected from the 
pellets coated with 10, 15 or 20% polymer weight gain. Although a decrease in 
the drug release rate from uncoated pellets was observed, the drug release 
properties of melt-extruded pellets coated with Eudragit® L 30 D-55 were stable 
after storage for 1 and 3 months at 40C/75% RH in sealed HDPE containers with 
silica desiccants. Table 5.4 demonstrates the drug release properties of beads 
coated with 10% weight gain of polymer.   
5.4 CONCLUSIONS 
The calculation of Hansen solubility parameters was demonstrated to be a 
useful method for predicting the miscibility of drug/polymer blends used a novel 
melt-extrusion and spheronization process. The drug release properties of matrix 
beads containing PEO, guaifenesin and GMS were not stable upon storage at 
accelerated conditions although the water content and dimensional structure of 
pellets did not change. Despite miscibility of the drug/polymer blend, the pellets 
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were morphologically unstable since PEO and guaifenesin recrystallized upon 
storage as detected by SEM and X-ray diffraction studies. Furthermore, reduction 
in the drug release rate was contributed to agglomeration of pellets during 
dissolution testing. The addition of ethylcellulose to the extruded powder blend 
and film-coating with Eudragit® L 30 D-55 stabilized the drug release properties 
of the thermally processed pellets. Furthermore, film-coating was demonstrated 
to be an efficient process for providing melt-extruded beads with pH-dependent 
drug release properties despite the use of low melting point of thermal carriers. 
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Guaifenesin Model Drug 20 20
PEO (POLYOX™ Mw. 4 x 106) Thermal Carrier 78 63
Ethylcellulose (Ethocel® 100FP) Release Modifying Agent 0 15




Table 5.2: Hansen solubility parameters calculated using the group contribution 







δ t δ d δ p δ h
Guaifenesin 25.85 18.88 5.57 16.76
PEO 22.87 17.78 11.11 9.13




Table 5.3: Influence of storage time at 40°C/75% RH in sealed HDPE containers 









Initial 2.41 ± 0.33 156 ± 23
1 Month 40°C/75% RH 2.79 ± 0.57 179 ± 31
3 Months 40°C/75% RH 2.70 ± 0.75 164 ± 26




Table 5.4: Drug release properties of formulation 1 pellets coated with 10% 
weight gain of Eudragit® L 30 D-55. (n = 6, USP 27 Apparatus 2, 
Method A, 2 h in 750 mL of 0.1 N HCl followed by 6 h in 900 mL 








SAMPLE % DRUG RELEASED   2 HR IN 0.1N HCl
% DRUG RELEASED   
1 HR pH 6.8 PBS
Initial 0 53.2
1 Month 40°C/75% RH 0 51.3















Figure 5.1: Pellets containing PEO, guaifenesin and GMS before and after 
spheronization for 15 min using a novel melt extrusion process.  













Figure 5.2: Thermal properties of guaifenesin, PEO (Mw. 4,000,000) and melt-
extrudates of blends (n = 3).  
Key: A. Guaifenesin; B. PEO; C. Extrudate—10% Guaifenesin, 90% 
PEO; D. Extrudate—20% Guaifenesin, 80% PEO; E. Extrudate—30% 

































Figure 5.3: Thermal gravimetric analysis of pellet formulation components and 
physical blends prior to melt-processing.  
Key: A. Guaifenesin; B. GMS; C. Ethylcellulose; D. Physical blend of 









































Figure 5.4: Stability of guaifenesin release rate from formulation 1 melt-extruded 
pellets upon storage at 40°C/75% RH in sealed HDPE containers 
with silica desiccants (n = 6, USP 27 Apparatus 2, 900 mL of 0.1 N 
HCl, 37°C, 100 rpm). 
























Figure 5.5: SEM analysis of the surface of spherical pellets upon storage at 
accelerated conditions in sealed HDPE containers with silica 
desiccants.  






























Figure 5.6: X-ray diffraction profiles of pellet formulation components and melt-
extruded beads before and after storage at 40°C/75% RH in sealed 
HDPE containers with silica desiccants.  
Key: A. GMS; B. PEO (Mw. 4,000,000); C. Guaifenesin; D. Powder blend; E. 







































Figure 5.7: Stability of guaifenesin release rate from formulation 2 melt-extruded 
pellets containing ethyl cellulose upon storage at accelerated 
conditions in sealed HDPE containers with silica desiccants (n = 6, 
USP 27 Apparatus 2, Method A, 2 h in 750 mL of 0.1 N HCl 
followed by 6 h in 900 mL of pH 6.8 phosphate buffer, 37°C, 100 
rpm).  







































Figure 5.8: Influence of Eudragit® L 30 D-55 weight gain on the guaifenesin 
release profile of HME spherical pellets (n = 6, USP 27 Apparatus 
2, Method A, 2 h in 750 mL of 0.1 N HCl followed by 6 h in 900 
mL of pH 6.8 phosphate buffer, 37°C, 100 rpm).  
Key:  5%;  10%;  15%; ▲ 20%. 
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Chapter 6: Physicochemical characterization and mechanisms of 
release of theophylline from melt-extruded dosage forms        
based on a methacrylic acid copolymer 
 
6.1 INTRODUCTION 
Controlled delivery of bioactive agents is a major focus of pharmaceutical 
research since multiple dosing regimens often present problems with patient 
compliance, toxicity and therapeutic index (Sood 2003). Polymeric drug carrier 
systems have been widely studied to sustain, modify or target drug delivery.  
Hot-melt extrusion (HME) of thermoplastic polymers have been used to 
produce a variety of controlled release dosage forms, including pellets, granules, 
tablets, suppositories, transdermal systems and ophthalmic inserts (Breitenbach 
2002, McGinity 2003, Zhu 2002). Acryl-EZE® is a pre-mixed excipient blend 
optimized for film-coating that is based on the methacrylic acid copolymer 
Eudragit® L 100-55. Although researchers have studied the pH-dependent drug 
release properties of melt-extruded bead matrices containing the acrylic 
copolymer Eudragit® Preparation 4135 F (Young 2003), the thermal processing 
applications of Acryl-EZE® have not been investigated. 
Mixtures of polymers, particularly cellulose ethers, are useful in 
regulating the drug release properties of dosage forms (Pose-Vilarnovo 2004). In 
tablet matrices, excipient mixtures not only modify drug release rate by 
producing gel barriers of varying consistency (Vazquez 1996), but they can also 
change the kinetics of drug release (Sung 1996). These effects are often due to 
interactions between the excipients that modify the microenvironment through 
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which the drug has to diffuse, particularly matrix viscosity and/or polarity 
(Alvarez-Lorenzo 1999, Alvarez-Lorenzo 2001). 
Matrix systems containing hydrophilic polymers have been widely 
studied since drug release is controlled by a combination of polymer swelling, 
erosion and drug diffusion through the hydrated gel (Di Colo 2001). Methocel® 
(hydroxypropyl methylcellulose) polymers are linear non-ionic cellulose ethers 
commonly used in controlled release systems. The properties of HPMC matrices 
have been extensively studied regarding both mechanistic and technological 
factors involved in drug release (Ford 1991, Shah 1993, Mahaguna 2003). The 
Carbopols are anionic, high molecular weight polymers of acrylic acid. Several 
researchers have studied tablet formulations containing Carbopol® polymers to 
produce zero-order or near zero-order drug release kinetics (Capan 1989, Perez-
Marcos 1991).  
The purpose of the current study was to investigate the physicochemical 
properties of melt-extruded dosage forms based on Acryl-EZE® and to determine 
the influence of Methocel® K4M Premium and Carbopol® 974P on the 
mechanisms and kinetics of drug release. The physical and chemical stability of 
materials during thermal processing was studied using thermal gravimetric 
analysis and HPLC. The mechanism and kinetics of drug release were 
investigated using model fitting and matrix hydration and erosion studies.   
6.2 MATERIALS AND METHODS 
 6.2.1 Materials 
Acryl-EZE® was donated by Colorcon (Westpoint, PA). Anhydrous 
theophylline, anhydrous citric acid and glacial acidic acid were purchased from 
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Spectrum Chemical (Gardenia, CA). Carbopol® 974P (carbomer) and Methocel® 
K4M Premium (hydroxypropyl methylcellulose) were provided by Noveon 
(Cleveland, OH) and Dow Chemical (Midland, MI), respectively. All materials 
were passed through a 30 mesh screen prior to processing. Triethyl citrate (TEC) 
was donated by Moreflex (Greensboro, NC). Acetonitrile was purchased from 
EM Science (Gibbstown, NJ).  
6.2.2 Thermal analysis of materials 
Thermal gravimetric analysis (TGA) was performed using a Perkin-Elmer 
(Norwalk, CT) 7-series Thermogravimetrical Analyzer. The temperature ramp 
speed was set at 10°C/min, and the percentage weight loss of the samples was 
monitored from 25°C to 600°C. Volatiles were removed from samples by storing 
powders under vacuum with desiccants at 25°C for 72 h prior to thermal studies. 
6.2.3 Melt-extrusion of dosage forms 
The hot-melt extruded formulations consisted of theophylline, Acryl-
EZE®, triethyl citrate and an optional gelling agent, Methocel® K4M Premium or 
Carbopol® 974P. The blends were mixed for 5 min in a ceramic mortar and pestle 
prior to addition of the liquid plasticizer TEC. After the plasticizer was 
geometrically added to the powder blends, the formulation was mixed for an 
additional 5 min.  The blends were then extruded using a Randcastle 
Microtruder® RCP-0750 (Cedar Grove, NJ) single-screw extruder. The extruder 
was equipped with a Nitralloy 135M screw (3:1 compression ratio with flight 
configuration containing feed, compression and mixing sections). The 
temperature of the extruder barrel zones and die were set as follows using 
external temperature controllers: Zone 1 = 90°C, Zone 2 = 95°C, Zone 3 = 110°C 
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and Die = 115°C. A 6 mm cylindrical die and a screw speed of 20 rpm were 
employed for tablet production. The cylindrical extrudates were manually cut 
into tablets weighing approximately 250 mg.  
A 1.2 mm cylindrical die and a screw speed of 10 rpm were employed for 
pellet production. After exiting the die, the polymeric strand was fed into a 
Randcastle Pelletizer RCP-2.0 and uniformly cut into cylindrical pellets.  A 75 g 
sample of pellets was then transferred into a Caleva Model 120 Spheronizer 
(Dorset, England) that was maintained at 60-70°C using a Milwaukee™ Model 
1220 (International Tool Corporation; Davie, FL) heat gun. A detailed 
description of the HME and spheronization process was reported earlier (Young 
2002). The pellets were spheronized for approximately 15 min.  
6.2.4 In vitro drug release studies 
Dissolution studies were performed according to Apparatus 2 guidelines 
(paddle method) of USP 27 in a Van Kel VK7000 Dissolution Tester equipped 
with an auto sampler (Model VK 8000). The medium (900 mL) was maintained 
at 37°C and agitated at a speed of 50 rpm. Complete drug release was determined 
after mixing the vessel contents with a homogenizer for 5 min. The enteric 
dissolution properties of tablets were studied using dissolution testing for 2 h in 
0.1 N HCl followed by testing in pH 6.8 phosphate buffered solution (PBS, 50 
mM).  
Samples were analyzed for drug content using a Waters HPLC system 
equipped with a photodiode array detector (Model 996) extracting at 281 nm.  
Samples were pre-filtered through a 0.2 µm membrane (Gelman Laboratory, 
GHP Acrodisc) to remove insoluble excipients. An auto sampler (Model 
717plus) was used to inject 10 µL samples, and the data were collected and 
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integrated using Empower® Version 5.0 software.  The column was an Alltech 
Inertsil™ ODS-3 3 µm, 150 x 4.6 mm, and the mobile phase contained a mixture 
of water:acetonitrile:glacial acetic acid in volume ratios of 845:150:5 and 1.156 
g/L of sodium acetate trihydrate. The retention time of the theophylline was 
approximately 3.6 min.  Linearity was demonstrated from 1 to 100 mg/µL (r2 ≥ 
0.998) and injection repeatability was approximately 1% relative standard 
deviation for 6 injections. 
6.2.5 Analysis of Dissolution Data 
The mechanism of drug release from cylindrical extrudates (0.6 cm x 6 
cm) during dissolution investigations in 0.1 N HCl or pH 6.8 PBS was 
determined using equation 6.1, the Korsmeyer-Peppas model. 
 
Mt/M∞  = atn       (Eq. 6.1) 
 
where Mt corresponds to the amount of drug released in time t, M∞ is the total 
amount of drug that must be released at infinite time, a is a constant 
incorporating structural and geometric characteristics of the drug dosage form 
and n is the release exponent. Drug release data were employed for determination 
of the release exponent where Mt/M∞ ≤ 0.6. 
The drug release kinetics of tablets (250 mg) during enteric dissolution 
testing were determined by finding the best fit of the dissolution data (Mt/M∞ ≤ 
0.85) to distinct models: zero-order (6.2), first-order (6.3), Hixson-Crowell (6.4) 
and Higuchi (6.5).  
 
Mt = M0 +  K0 t        (Eq. 6.2) 
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ln Mt = ln M0 +  K1 t        (Eq. 6.3) 
Mt1/3 - M01/3 =  KS t        (Eq. 6.4) 
Mt = KH t1/2         (Eq. 6.5) 
 
where Mt is the amount of drug released at time t, M0 is the total amount of drug 
in the solution at t = 0 (usually, M0 = 0), and K0, K1, KS and KH are the kinetic 
rate constants for the zero-order, first-order, Hixson-Crowell and Higuchi 
models, respectively. 
6.2.6 Hydration and erosion studies 
The hydration and erosion of melt-extruded tablets (250 mg) were studied 
in 0.1 N HCl and pH 6.8 PBS under conditions identical to those described above 
for dissolution testing. Tablets were carefully removed from the dissolution 
vessel at predetermined time-points, and the wet weight was measured. The 
dosage forms were then dried at 55°C in a vacuum with desiccants for 7 days.  
The remaining dry weight was determined gravimetrically after equilibrating the 
dried tablets at 25°C in a vacuum with desiccants for 24 h. The percent hydration 
and mass remaining of tablets were determined gravimetrically according to the 
following equations: 
 
% Hydration = 100(W2-W3)/W3     (Eq. 6.6) 
% Mass Remaining = 100(W3/W1)    (Eq. 6.7) 
  
where W1 is the initial dry weight of the tablet, W2 is the wet weight and W3 is 
the remaining dry weight after dissolution testing. Three tablets were used for 
each time-point. 
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6.3 RESULTS AND DISCUSSION 
Matrix tablets based on Acryl-EZE® were melt-extruded using the 
formulations listed in Table 6.1. All formulations contained 20% theophylline 
based on the total formulation weight and 25% TEC based on the weight of 
Acryl-EZE®. Furthermore, the concentrations of the gelling agents studied were 
2.5, 5 and 10%. The formulations containing Methocel® K4M required more 
drive amps and created higher pressures at the die when compared to the other 
blends. Furthermore, the mixture containing 10% Methocel® could not be 
extruded using the processing temperatures and plasticizer levels employed in the 
current study.  
6.3.1 Thermal stability of materials 
The thermal stability of materials was studied using TGA and HPLC. 
TGA is useful for determining processing temperatures since this method 
indicates thermal stability by measuring weight loss due to decomposition as a 
function of temperature. As seen in Figure 6.1, formulation components did not 
experience weight loss at the processing temperatures, which ranged from 90°C 
to 115°C. Acryl-EZE® exhibited a transition in the thermogram at approximately 
170°C. A blend of Eudragit® L 100-55 and TEC also exhibited a weight loss at 
this temperature, whereas the weight of Eudragit® L 100-55 alone remained 
constant at temperatures below 200°C. Thus, the transition in the thermogram of 
Acryl-EZE® at 170°C was due to the loss of TEC. Although TGA provides a 
working temperature range, additional techniques are required to fully 
characterize the chemical stability of materials. The chemical stability of 
theophylline after HME was verified using a USP reversed-phase HPLC method. 
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6.3.2 In vitro drug release studies 
Melt-extruded matrix tablets based on Acryl-EZE® exhibited pH-
dependent theophylline release properties. As seen in Figure 6.2, melt-extruded 
tablets containing Acryl-EZE®, theophylline and TEC released approximately 
10% drug after 2 h in 0.1 N HCl. Approximately 75% drug was released after 4 
h, which included 2 h in 0.1 N HCl and 2 h in pH 6.8 PBS. The rapid drug 
release rate observed in the pH 6.8 medium was due to the pH-dependent 
solubility properties of the matrix polymer, Eudragit® L 100-55. The anionic 
methacrylic acid copolymer is widely employed for pH-dependent drug delivery 
applications since it solubilizes in aqueous media above pH 5.5. 
It can also be seen in Figure 6.2 that Methocel® K4M Premium increased 
theophylline release in 0.1 N HCl. Since Eudragit® L 100-55 is insoluble in this 
medium, the hydrophilic polymer changed the drug release rate by increasing 
matrix permeability. Pollock and Balwinski (2000) studied Methocel® as a 
porosity modifier in an ethylcellulose compression coated system and noted that 
HPMC accelerated drug release by swelling and opening channels through which 
medium could enter the core. The current study also found that the amount of 
drug released during the first 2 h of dissolution testing increased with increasing 
HPMC concentration.   
Although HPMC was a porosity modifier in 0.1 N HCl, the high 
molecular weight polymer decreased the rate of theophylline release in the pH 
6.8 medium. Methocel® controlled drug diffusion by forming a gel matrix in the 
medium where Eudragit® L 100-55 was soluble. Additionally, the higher 
concentration of HPMC further decreased the rate of theophylline release due to 
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formation of a stronger gel matrix that was less libel to erosion (Gao 1996, 
Maggi 1999, Ranjani 1998).  
The influence of Carbopol® 974P on the theophylline release rate is 
illustrated in Figure 6.3. Like HPMC, Carbopol® increased drug release in the pH 
1.0 medium by increasing matrix permeability due to polymer swelling in the 
presence of water. However, this polymer more significantly reduced the rate of 
theophylline release in the pH 6.8 medium when compared to HPMC. The gel 
layer of Carbopol® containing matrix tablets is due to a chemically crosslinked 
network, while Methocel® containing tablets exhibit virtual crosslinking and gel 
formation as a result of polymer chain entanglement. Perez-Marcos (1994) and 
coworkers reported that Carbopol® 974 formed more viscous gels than 
Methocel® K4M when used at the same concentrations  
The dissolution profiles of the tablets containing 5 or 10% Carbopol®, 
which exhibited complete drug release after approximately 14 h, were not 
significantly different as illustrated in Figure 6.3 (f1 = 5, f2 = 59). Generally, 
dissolution curves are considered equivalent when difference values (f1) are less 
than 15 and similarity values (f2) are greater than 50. However, the matrices 
containing 2.5% Carbopol® significantly extended the duration of drug release. 
Complete theophylline release was not obtained until approximately 20 h of 
dissolution testing.  
The theophylline release profiles of Carbopol® containing tablets did not 
appear to be influenced by changes in the medium pH during enteric dissolution 
investigations. However, dissolution studies at pH 1.0 or 6.8 without media 
changes revealed that the matrix tablets exhibited pH-dependent drug release 
properties. The formulation containing 2.5% Carbopol® released approximately 
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68% theophylline after 10 h of enteric dissolution testing, while 52% and 83% 
drug were released after 10 h in the pH 1.0 and 6.8 media, respectively. 
Furthermore, concentration of the additive more significantly influenced drug 
release in 0.1 N HCl when compared to pH 6.8 PBS. Thus, the 2.5% Carbopol® 
tablets exhibited a more extended duration of theophylline release due to less 
significant changes in matrix permeability in the pH 1.0 medium.  
 As illustrated in Figure 6.4, Carbopol® 974P also significantly influenced 
the drug release properties of melt-extruded beads. Drug release rate increased in 
the pH 1.0 medium and decreased in the pH 6.8 medium upon addition of the 
polymer. However, unlike the findings of dissolution investigations of matrix 
tablets, Carbopol® only extended theophylline release for approximately 1 h 
longer than the melt-extruded beads without the polymeric additive. Furthermore, 
the 2.5% Carbopol® beads did not exhibit a significantly extended dissolution 
profile when compared to the beads containing 5 or 10% of the polymer. The 
rapid release of theophylline was due to the high surface area to volume ratio of 
beads. Other researchers have noted that matrix geometry significantly influences 
drug release rates from systems containing swellable polymers (Katzhendler 
1997, Siepmann 2000). Matrix tablets were employed for model fitting and 
hydration/erosion studies since they exhibited a longer duration of drug release. 
6.3.3 Mechanisms and kinetics of drug release 
The mechanism of drug release from matrices containing swellable 
polymers is complex and not completely understood. Some systems may be 
classified as either purely diffusion or erosion controlled, while most systems 
exhibit a combination of these mechanisms (Siepmann 2001). The Korsmeyer-
Peppas model is used to analyze drug release from pharmaceutical dosage forms 
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when the release mechanism is not well known or when more than one type of 
release phenomena is involved (Korsmeyer 1983). The exponent, termed the 
release exponent or n value, was studied by Peppas and coworkers (1985) to 
characterize different drug release mechanisms from thin films. They noted that 
profiles with n = 0.5 exhibited a drug release mechanism controlled by Fickian 
diffusion, while drug release rate was independent of time and controlled by a 
swelling mechanism when n = 1. A zero-order release mechanism is also known 
among polymer scientists as case-II transport. Values of n between 0.5 and 1.0 
were regarded as an indicator for the superposition of both phenomena, and the 
drug release mechanism was termed anomalous (non-Fickian) transport.  
The values of n for cylindrical systems were later determined (Ritger 
1987): n = 0.45 (Fickian diffusion), 0.45 < n < 0.89 (anomalous transport) and n 
= 0.89 (case-II transport). Furthermore, when determining the n exponent, only 
the portions of the release curve where Mt/M∞ ≤ 0.6 should be used. Another 
commonly overlooked requirement is that drug release occurs in a one-
dimensional way, thus the length to width ratio of the device must be at least 10 
(Costa 2001).  
Drug release data from the dissolution investigations of cylindrical 
extrudates (0.6 cm x 6.0 cm) in either pH 1.0 or pH 6.8 medium were used for 
model fitting. As illustrated in Table 6.2, dissolution data fit the model well as a 
correlation coefficient (r2) greater than 0.99 was obtained in all cases. The tablets 
without a swelling agent approached a release mechanism described by Fickian 
diffusion in 0.1 N HCl and exhibited primarily case-II transport in pH 6.8 PBS.  
The difference in release mechanism as a function of medium pH was a result of 
the pH-dependent solubility properties of Eudragit® L 100-55.  
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The tablets containing 2.5% Methocel® K4M or Carbopol® 974P also 
exhibited near Fickian diffusion controlled release in 0.1 N HCl, but an 
anomalous (non-Fickian) diffusional mechanism became apparent as the 
concentration of the gelling polymers increased. The additives resulted in an 
anomalous mechanism of drug release by increasing matrix permeability in the 
medium where Eudragit® L 100-55 was insoluble. Furthermore, the release 
exponent ranged form 0.64 to 0.80 in pH 6.8 PBS for all Methocel® and 
Carbopol® containing extrudates. Theophylline release from these matrices was 
controlled by a combination of polymer swelling, matrix erosion and diffusion of 
the drug in the hydrated polymer matrix. 
The kinetics of drug release from Carbopol® containing tablets (250 mg) 
were analyzed using multiple drug release models as illustrated in Table 6.3. 
Only melt-extruded tablets containing the anionic swelling agent were studied 
since these dosage forms did not exhibit a biphasic drug release profile as a result 
of the media change during enteric dissolution testing. Tablets with 10% 
Carbopol® exhibited the highest correlation coefficient (r2) with the zero-order 
model, while the formulations containing 2.5 or 5% of the polymer best fit the 
Higuchi model. Siepmann and Peppas (2001) noted that information from the 
Higuchi equation should be viewed with caution when studying devices 
containing swellable polymers since the model assumes constant diffusivities and 
dimensions of the devise during drug release. Carbopol® swells significantly 
during dissolution testing, and the diffusion coefficients of water and 
incorporated drugs are strongly concentration dependent (Siepmann 1999). Thus, 
swellable systems often exhibit square root of time kinetics although drug release 
is not necessarily based on a simple drug diffusion mechanism.  
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6.3.4 Hydration and erosion studies 
The hydration and erosion of matrix tablets during dissolution 
investigations were studied to determine the influence of gelling agents on the 
mechanism of drug release from melt-extruded tablets. The results of these 
studies supported the findings of fitting to the Korsmeyer-Peppas model. Figure 
6.5 illustrates the hydration, mass remaining and drug release profiles for tablets 
containing 2.5%. The results indicate that drug release was primarily diffusion 
controlled in 0.1 N HCl as there was minimal hydration or erosion of the matrix. 
When the medium was changed to pH 6.8 PBS, the diffusional exponent (n) 
increased to 0.80 as a result of significant tablet erosion. The low concentration 
of HPMC formed a gel with insufficient strength to maintain the matrix structure 
upon dissolution of Eudragit® L 100-55. 
As illustrated in Figure 6.6, similar results were found for the 2.5% 
Carbopol® tablets in 0.1N HCl. Drug release was not significantly influenced by 
water uptake or tablet erosion. Furthermore, formation of a hydrogel in pH 6.8 
PBS prevented significant matrix erosion and resulted in an anomalous (non-
Fickian) drug release mechanism. The tablets absorbed approximately 1.5 times 
their weight in water after 4 h in pH 6.8 PBS. The percent water uptake and mass 
loss of these tablets were stable between the 8 and 20 h time points. Furthermore, 
investigators have noted that Carbopol® forms mechanically strong matrices at 
low concentrations due to the chemically crosslinked structure of the polymer 
that swells, but does not dissolve, in water (Perez-Marcos 1994).  
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6.3.5 Stability of drug release 
Matrix tablets containing 2.5% Carbopol® were stored at 40°C/75% RH 
in induction sealed HDPE containers containing silica desiccants. Drug release 
rates from polymeric often decrease upon storage due to changes in the 
dimensional structure of the matrix (Omelczuk 1993, Zang 2001). As seen in 
Figure 6.7, the dissolution profiles of matrix tablets containing 2.5, 5 or 10% 
Carbopol® were stabled upon storage for 3 months at accelerated conditions. 
These results are in agreement with the findings of previous researchers who 
have noted that melt-extruded matrix dosage forms do not exhibit changes in 
matrix structure upon storage since compression and intense mixing of molten 
materials during processing results in a product with low free volume (Kidokoro 
2001). 
6.4 CONCLUSIONS 
Although Acryl-EZE® is a pre-mixed excipient blend optimized for film-
coating applications, the current study demonstrated the effectiveness of a melt-
extrusion process to prepare controlled release systems based on Acryl-EZE®. 
The blend was stable during thermal processing, and resulted in dosage forms 
with pH-dependent dissolution properties.  
Results also illustrated the influence of the physicochemical properties of 
gelling agents on the mechanism and kinetics of drug release from melt-extruded 
dosage forms. At low concentrations, Carbopol® 974P was more effective than 
Methocel® K4M Premium at controlling theophylline delivery in a medium 
where Eudragit® L 100-55 exhibited solubility. These findings were due to 
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chemical crosslinking nature of the polymeric additive which created a gel 
network that did not dissolve during dissolution investigations. 
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1 2 3 4 5 6
Theophylline 20 20 20 20 20 20
Acryl-EZE 64 62 60 62 60 56
TEC 16 15.5 15 15.5 15 14
Methocel K4M Premium - 2.5 5 - - -







Table 6.2: Korsmeyer-Peppas model fitting of dissolution data from cylindrical 
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Table 6.3: Model fitting of drug release data from enteric dissolution investigations of Carbopol containing 
tablets (paddle method, 2 h in 0.1 N HCl followed by 8 h in pH 6.8 phosphate buffer, 900 mL, 









r 2 K 0 r 2 K 1 r 2 K S r 2 K H
2.5 0.9844 2.87 0.8275 0.18 0.9015 0.14 0.9933 12.31
5 0.9884 3.49 0.8418 0.19 0.9083 0.16 0.9928 13.94














































Figure 6.1: Thermal gravimetric analysis of formulation components.  








































Figure 6.2: Influence of Methocel® K4M Premium on the theophylline release 
properties of melt-extruded Acryl-EZE® tablets (paddle method, 2 h 
in 0.1 N HCl followed by 8 h in pH 6.8 phosphate buffer, 900 mL, 
37°C, 50 rpm, n = 6).  






































Figure 6.3: Influence of Carbopol® 974P on the theophylline release properties of 
melt-extruded Acryl-EZE® tablets (paddle method, 2 h in 0.1 N HCl 
followed by 22 h in pH 6.8 phosphate buffer 900 mL, 37°C, 50 rpm, 
n = 6).  






































Figure 6.4: Influence of Carbopol® 974P on the theophylline release properties of 
melt-extruded Acryl-EZE® beads (paddle method, 2 h in 0.1 N HCl 
followed by 3 h in pH 6.8 phosphate buffer, 900 mL, 37°C, 50 rpm, 
n = 6).  































Figure 6.5: Influence of 2.5% Methocel® K4M Premium on the hydration, 
erosion and drug release properties of melt-extruded Acryl-EZE® 
tablets (paddle method, 2 h in 0.1 N HCl followed by 6 h in pH 6.8 
phosphate buffer, 900 mL, 37°C, 50 rpm, Hydration/Erosion: n = 3, 
Drug Release: n = 6).  
































Figure 6.6: Influence of 2.5% Carbopol® 974P on the hydration, erosion and drug 
release properties of melt-extruded Acryl-EZE® tablets (paddle 
method, 2 h in 0.1 N HCl followed by 18 h in pH 6.8 phosphate 
buffer, 900 mL, 37°C, 50 rpm, Hydration/Erosion: n = 3, Drug 
Release: n = 6).  







































Figure 6.7: Stability of theophylline release rate from melt-extruded Acryl-EZE® 
tablets containing Carbopol® 974P upon storage for 3 months at 
40°C/75% RH in induction sealed HDPE containers with silica 
desiccant (paddle method, 2 h in 0.1 N HCl followed by 8 h in pH 
6.8 phosphate buffer, 900 mL, 37°C, 50 rpm, n = 6).  
Key:  2.5%, initial; 2.5%, stored;  5%, initial;  5%, stored;  
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